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INTRODUCTION 
Catecholamine Receptors 
Hormones elicit a multitude of biochemical and physiological effects 
In a large variety of tissues and cells. One of the premises of hor­
mone action is that hormone responsive cells contain specific receptor 
molecules which recognize specific hormones. Simply, -eceptors are 
what hormones interact with to elicit their characteristic responses. 
Catecholamines, such as epinephrine and norepinephrine, have been 
thoroughly studied, and in 1948, Ahlquist (1) proposed that there were 
two distinct types of receptors for these hormones. These two receptor 
types were termed alpha (a) and beta (p), and discrimination was based 
upon the relative potencies of ssveral catecholamines for eliciting 
various physiological responses. Both of these receptor proteins are 
located on the plasma membrane and recently the preceptor has been 
purified and found to be composed of 58,000 da1ton subunlts (2). 
Although the original classification of or and P-receptors proved to 
be very useful in describing adrenergic response», additional studies 
demonstrated it needed further refinement. In 1967, Lands et al. 
(3) found two subtypes of (Preceptors which were termed and gg; 
P^ -receptors have approximately equal affinity for epinephrine and 
norepinephrine, whereas g^ -receptors have a higher affinity for 
epinephrine. A similar subclassification of «-receptors into 
and has been made (4) and is based upon the affinities of specific 
receptor antagonists for these two receptors. a^ -Receptors have rela­
tively high affinities for prazosin and phenoxybenzamine while 
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receptors have a high affinity for yohimbine (5). The heart contains 
both and c^ a^drenergic receptors (6) and 3-receptors of the 
subtype (7). At present, differential sensitivity to blockade by 
receptor antagonists is the most commonly used criterion for distinguishing 
cr and P-responses. 
In almost all tissues examined, 3-receptors have been found to 
mediate catecholamine-induced accumulation of cANP. This was originally 
shown by Sutherland's group (8) in studies of epinephrine effects on 
liver glycogen metabolism. Recently, it has been proposed that 3-
adrenergic hormones activate adenylate cyclakc by relieving the inhibi­
tion of the 0-receptor on the adenylate cyclase activating protein (GTP 
regulatory protein) (9). crReceptors are thought to mediate catecholamine 
responses without activating adenylate cyclase. This was fitc-t sug­
gested by Sherline et al. (10) when they noted an apparent dissociation 
of catecholamine effects on cAMP and glycogenolysis in the liver. There 
is an accumulating body of evidence which suggests that many a-receptor 
responses occur as a result of changes in cytosolic calcium concentra­
tion (11). This has been illustrated convincingly in the liver cell 
where catecholamines stimulate rapid efflux of calcium from the 
mitochondria by an a-receptor mechanism (12, 13). Although Miche11 
(14, 15) and Fain (16) have suggested that phosphatidylinositol break­
down in the membrane may account for changes in calcium distribution in 
the cell, Exton's group has recently shown that this process 
occurs too slowly to serve as a primary "messenger" of OJ-adrenergic 
hormone action (17). A possible messenger of «-adrenergic hormones remains 
to be identified. In some cells, a-receptor stimulation results in 
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an inhibition of adenylate cyclase activity (18, 19). In these cells, 
crreceptor stimulation decreases cAMP levels and the cAMP response to 
8-adrenergic hormones (20-22). Rodbe11 ' s model of hormonally regulated 
adenylate cyclase suggests that oradrenergic hormones may produce this 
effect by activating a GTP regulatory protein which functions to 
inhibit adenylate cyclase (9). Such inhibitory actions of o-adrenergic 
hormones may perhaps serve as modulators of P-receptor responses. 
An alternate mechanism for modulating the p-receptor response in­
volves regulation by -^adrenergic hormones, themselves. 3-Receptors 
become desensitized and nonfunctional upon prolonged exposure to P-
agonists (23-27). Desensitization has been examined in a number of 
tissues containing adenylate cyclase coupled receptors, and these 
studies suggest that at least two types of g-adrenergic desensitization 
exist. The loss of p-stimulated cyclase activity following g-adrenergic 
stimulation has been termed homologous densensitization (24). Homologous 
desensitization appears to consist of two distinct reactions. The 
first reaction is rapid and results in an uncoupling of the p-receptor 
from adenylate cyclase (28), and the second reaction occurs with longer 
incubation and involves loss of P-receptors from the membrane surface 
(25). Heterologous desensitization describes the phenomenon where 
P-stimulated cyclase activity is reduced in response to all activators 
of adenylate cyclase (24). Both homologous and heterologous desensitiza­
tion of the p-receptor result in a diminished cAMP response when cells 
are challenged with further additions of hormone. While the exact 
mechanism(s) of P-receptor desensitization are not totally clear. 
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present evidence suggests that this process may be as complex as the 
enzymic cascade reactions which are elicited by these hormones. 
Cardiac Muscle Contraction 
In the mammalian heart, calcium ions are the prime regulators of 
contraction (29). Removal of calcium from the perfusion media causes 
the heart to stop beating. Harary and Wallace (30) have shown that 
contraction of beating heart cells also has an absolute requirement for 
medium calcium. Fablato and Fablato's (31, 32) studies with skinned 
cardiac fibers suggest that external calcium initiates contraction by 
triggering the release of calcium from Internal stores. These workers 
found that quantities of calcium significantly less than that required 
to activate cardiac contraction (33) induced the release of calcium 
from the sarcoplasmic reticulum. The resulting rise in myoplasmlc 
calcium results In the binding of calcium to troponin C and relieves 
the inhibition of the troponin-tropomyosin complex on actin-activated 
myosin ATPase activity (34). Relaxation of contraction occurs fol­
lowing the uptake of calcium by the sarcoplasmic reticulum. This 
2+ 
reactlon is thought to be catalyzed by a Ca -ATPase present in the 
sarcoplasmic reticulum membrane (35, 36). 
Catecholamine stimulation of the heart increases the heart rate, 
peak tension, rate of tension development, and rate of relaxation (3°. . . 
Although of-adrenerglc effects on contraction have been observed in the 
heart (38, 39) and in beating heart cells (40), the cAMP-medlated 
effects of the catecholamines are best understood. Cyclic AHP-effects 
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of the catecholamines are produced by modification of at least three 
steps in the cardiac contraction cycle. Calcium entry into the myo­
cardial cell is increased following epinephrine stimulation (41, 42). 
This effect may be due to epinephrine's effect on cAMP because dibutyryl 
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cAMP increases the slow inward calcium current (43) and Ca uptake 
(44) of the heart. Catecholamine stimulation of calcium entry may be 
mediated by sarcolemmal protein phosphorylation since phosphorylation 
of sarcolemmal vesicles by cAHP-dependent protein kinase stimulates 
membrane calcium transport of these vesicles (45, 46). The stimulation 
of calcium influx by catecholamines could account for their effect on 
the beating rate of the heart. A second site of catecholamine action 
is the sarcoplasmic reticulum protein called phospholamban. Both 
cAMP-dependent (35, 36, 47) and calmodulin-dependent (48, 49) phosphoryla­
tion of phospholamban stimulate active calcium transport in isolated 
cardiac sarcoplasmic reticulum vesicles. In addition, phospholamban 
2+ 
phosphorylation stimulates the sarcoplasmic reticulum Ca -ATPase (35). 
Thus, it is now generally accepted that phospholamban phosphorylation 
stimulates calcium transport by stimulating the sarcoplasmic reticulum 
2+ 
Ca -ATPase (35, 36). That phospholamban regulates calcium transport 
"in vivo" is suggested by the findings that catecholamines stimulate 
calcium uptake (50) and the phosphorylation of a 22,000 dalton protein 
(51) in the sarcoplasmic reticulum of the perfused heart. Thus, 
phospholamban phosphorylation has been proposed to account for the 
stimulation of the relaxation rate by catecholamines in the heart (35). 
In addition, phosphorylation of phospholamban may account for increases 
in the tension and rate of cardiac contraction since calcium storage and 
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calcium efflux from cardiac sarcoplasmic reticulum vesicles are increased 
following phospholamban phosphorylation (35). Finally, present 
evidence suggests that catecholamines regulate cardiac contraction by 
modifying the contractile machinery directly. England (52) has shown 
that a strong correlation exists between incorporation of phosphate into 
troponin I and the onset of increased contractility in perfused hearts 
stimulated with epinephrine. Cyclic AMP-dependent phosphorylation of 
troponin I occurs in the intact myofibril "in vitro" (53) and phos­
phorylation has been shown to decrease the calcium sensitivity of the 
cardiac contractile proteins (54). Thus, troponin I phosphorylation 
may also account for catecholamine stimulation of the relaxation rate 
in the heart. Although there is both "in vitro" and "in vivo" evidence 
for cardiac muscle myosin phosphorylation (55, 56), the physiological 
role of this modification is not clear because cardiac myosin ATPase 
activity appears to be unaffected by phosphorylation (57). 
Glycogen Metabolism 
The study of glycogen metabolism has contributed significantly to 
the understanding of protein regulation by phosphorylation. Glycogen 
phosphorylase was the first protein shown to be regulated by reversible 
phosphorylation (58), and phosphorylase kinase (59) and glycogen 
synthase (60) were the second and third examples of this phenomenon. 
Both cAMP and cAMP-dependent protein kinase were discovered during the 
study of catecholamine regulation of glycogenolysis (61, 62). Glycogen 
metabolism is a highly regulated process which can respond rapidly to 
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changes in the cell's environment. This is an essential feature of 
this process since glycogen breakdown and synthesis must occur rapidly 
to meet the changing energy demands of the cell. 
The metabolism of glycogen in mammalian cells is essentially 
regulated by the activities of glycogen phosphorylase and glycogen 
synthase. Glycogen phosphorylase is the rate limiting enzyme for 
glycogen degradation, catalyzing the removal of glucosyl units from 
the glycogen molecule (63). Cori et al. (64) first reported that 
glycogen phosphorylase existed in two forms, a B form which was inactive 
without 5' amp and an A form which was not dependent upon 5' AMP for 
activity. Krebs and Fischer (58) subsequently demonstrated that the B 
and A forms represented dephospho- and phospho-forms of the protein, 
respectively. This same group later showed that activation of glycogen 
phosphorylase B occurred by phosphorylation of the protein at a single 
serine residue by phosphorylase kinase (65). Phosphorylase kinase also 
exists in an inactive and active form in muscle (66). Activation of 
this enzyme occurs by phosphorylation with a number of protein kinases 
including cAMP-dependent protein kinase and phosphorylase kinase (66). 
Recently, Walsh's group studied the phosphorylation of the cardiac 
enzyme of phosphorylase kinase (67). These investigators found that 
activation of the enzyme occurred by cAMP-dependent phosphorylation of 
the a'" or p-subunit, as well as by autophosphorylation of the a'-
subunit. Thus, cardiac phosphorylase kinase differs from the skeletal 
muscle enzyme since the latter enzyme is not activated by crsubunit 
phosphorylation (68). Glycogen synthase is the rate limiting enzyme 
for glycogen synthesis, catalyzing the transfer of the glucosyl moiety 
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of UDPG to a glycogen primer (69) in a reaction which is considered 
irreversible under physiological conditions (70). Villar-Palasi and 
Larner (71) first proposed the existence of interconvertible forms of 
glycogen synthase after observing that insulin treatment of skeletal 
muscle decreased the effect of the activator, glucose-6-phosphate, on 
glycogen synthase activity. Later, this group demonstrated that con­
version between the two forms of muscle glycogen synthase occurred by 
phosphorylation and dephosphorylation (60, 72). Phosphorylation in­
activates glycogen synthase and dephosphorylation activates the en­
zyme. The phosphorylated form of glycogen synthase is termed D due 
to its dependence upon glucose-6-phosphate for activity, and the de-
phosphorylated form is termed I due to its relative independence of 
glucose-6-phosphate for activity. Unlike glycogen phosphorylase, glyco­
gen synthase can be phosphorylated in multiple sites in reactions 
catalyzed by a number of kinases (73). Cohen's work indicates that 
skeletal muscle glycogen synthase can be phosphorylated on seven serine 
residues by five different kinases and that all seven sites may be phos­
phorylated "in vivo" (68). Cardiac glycogen synthase can be phosphorylated 
at three sites using a combination of cAMP-dependent and cAMP-
independent protein kinases (74, 75). Mitchell and Thomas' work (75) 
indicates that the extent c.F inactivation of cardiac glycogen synthase 
by phosphorylation depends upon the particular kinase used and the site 
which it phosphorylates. Thus, Inactivation of glycogen synthase in the 
cell may be more complex than simple incorporation of phosphate onto 
the enzyme. Recent evidence by McCullough and Walsh (76) suggests that 
heart glycogen synthase may be phosphorylated at 2 or 3 sites "in vivo;" 
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however, additional work is needed to describe the "in vivo" phosphoryla­
tion state of cardiac glycogen synthase. 
Dephosphorylation of the enzymes involved in glycogen metabolism 
is catalyzed by phosphoprotein phosphatase(s). Although four distinct 
phosphoprotein phosphatases have been identified in skeletal muscle, 
it is thought that a single enzyme (protein phosphatase 1) represents 
the major phosphatase for glycogen synthase, glycogen phosphorylase, 
and phosphorylase kinase (68). In the heart, phosphoprotein phosphatase 
exists as multiple molecular weight forms (77), has a broad substrate 
specificity (78, 79), is inhibited by glycogen (79), and is altered 
by nutritional and hormonal treatment (80, 81). 
In 1965, Robison et al. (82) reported that epinephrine treatment 
of perfused rat hearts caused an increase in cAMP followed by enhanced 
contractility and activation of glycogen phosphorylase. These results 
suggested that the appearance of glycogen phosphorylase A might be an 
important factor in coordinating glycogenolysis with muscle contraction. 
This idea was supported by subsequent studies which noted similar dose 
responses for epinephrine stimulation of glycogenolysis and muscle 
contraction (83, 84). Catecholamine activation of cardiac glycogen 
phosphorylase results from activation of phosphorylase kinase (85-87) 
which appears to result from cAMP-mediated activation of cAMP-dependent 
protein kinase (87-89). Cyclic AMP-independent activation of cardiac 
glycogen phosphorylase has been demonstrated only in diabetic rat hearts 
(90) or hearts depleted of glycogen (91). Thus, catecholamine effects 
on cardiac glycogen phosphorylase appear to be mediated by the &-
adrenergic receptor. Epinephrine has been reported to activate (92, 93), 
10 
inhibit (90, 91, 94), and have no effect (76, 82, 95) on cardiac glycogen 
synthase. Since many of these studies were conducted with perfused 
hearts, these variable responses may reflect variations in perfused 
heart preparations. Nuttall et al. (94) studied epinephrine effects 
on heart glycogen synthase in the intact animal and observed epinephrine 
inactivation of glycogen synthase. This study is consistent with the 
observed inactivation of glycogen synthase by catecholamines in other 
tissues (96-99), and is in keeping with catecholamine effects on heart 
glycogen phosphorylase. Additional studies are needed to fully clarify 
the effect of adrenergic hormones on heart glycogen synthase. 
Protein Thiolation 
The regulation of protein function by covalent modification is 
well-accepted as a mechanism for controlling cellular metabolism. The 
preceding discussion has emphasized the importance of protein phosphoryla­
tion in the regulation of contraction and glycogen metabolism in the 
hsart. Racciitly, s growing number of reports have suggested that protein 
thiolation (formation of mixed-disulfides between low molecular weight 
thiols and protein cysteine groups) may be another important form of 
covalent modification. In 1968, Modig (100) reported the occurrence 
of mixed-disulfides between proteins and glutathione. Subsequently, 
Harrap et al. (101) found that protein mixed-disulfides of both 
cysteine and glutathione were present in a variety of tissues in the 
rat. Interestingly, in the heart, nearly 50% of the total cellular 
sulfhydryls were in the form of protein mixed-disulfides, and nearly 
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80% of these disulfides were glutathione disulfides. Thus, a considerable 
proportion of intracellular glutathione may be in the form of protein 
mixed-disulfides in the heart. 
Recently, an accumulating body of evidence suggests that protein 
thiolation may be important in biological regulation. The activities 
of a number of proteins are modified by reaction with biological di­
sulfides. Glycogen synthase (102, 103), glycogen phosphorylase phosphatase 
(104), and phosphofructokinase (105) are reversibly inactivated by 
glutathione disulfide, whereas this compound activates fructose 1,6-
bisphosphatase (106) and glucose-6-phosphate dehydrogenase (107). The 
finding that some proteins are regulated by phosphorylation and thiola­
tion (glycogen synthase (75, 103), eukaryotic initiation factor-2 (108)) 
raises exciting questions concerning the effect of one modification on 
the other. Indeed, glycogen synthase dephosphorylation has recently 
been shown to be regulated by thiolation of synthase (109). The recent 
discovery of an enzyme activity which catalyzes thiolation and dethiola­
tion of proteins (110) raises the possibility that some functions of 
proteins "in vivo" may be regulated by reversible covalent modifications 
of their sulfhydryl groups. The level of glutathione protein-mixed di­
sulfide in rat liver shows a diurnal variation which is inversely cor­
related to the level of glutathione in this tissue (111). Additional 
studies by Isaacs and Binkley (112) have shown that dibutyryl cAMP 
increases the levels of hepatic mixed-disulfides in the rat, suggesting 
that cAMP may be involved in cellular protein thiolation. Recent 
studies by Keeling et al. (113) suggest that the pentose phosphate 
pathway may be regulated "in vivo" by protein mixed-disulfide formation. 
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This latter finding is in keeping with the observed activation of glucose-
6-phosphate dehydrogenase by glutathione disulfide (107). It is 
interesting to note that in the perfused heart, oxidized glutathione 
also stimulates the pentose phosphate shunt (114). Further studies 
are needed to clarify the role of thiolation in metabolic regulation. 
To demonstrate the physiological significance of this phenomenon, thiola­
tion of specific proteins will need to be related to changes in cellular 
function. 
Much of the work of hormone action in myocardial cells has hereto­
fore been examined in perfused hearts, "in situ" heart preparations, 
and the intact animal. In the present study, the use of beating heart 
cells to study hormone action is examined. The effects of a- and p-
adrenergic receptor stimulation on the heart cell beating rate are 
described and related to effects on the concentration of cAMP in the 
cell. Regulation of the P-receptor cAMP response by ffl-receptor 
stimulation is examined, and P-adrenergic desensitization is described. 
The effects of a- and P-receptor stimulation on glycogen phosphorylase 
activity, glycogen synthase activity, and protein phosphorylation in 
the heart cells are examined. Finally, thiolation of proteins in the 
heart cells is examined using a procedure described in this work. 
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MATERIALS AND METHODS 
Materials 
UDPG, glucose-6-phosphate, AMP, bovine serum albumin, lysozyme, 
rabbit liver glycogen, reduced and oxidized glutathione, iodoacetic acid, 
2,4-dinitrofluorobenzene, 1-epinephrine bitartrate, 1-isoproterenol 
bitartrate, 1-phenylephrine bitartrate, 1-norepinephrine bitartrate, 
clonidine, yohimbine HCl, and cycloheximide were purchased from Sigma 
Chemical Co. 1-Cysteine and 1-cystine were from GIBCO. All amino 
acids and vitamins for the culture media were purchased from GIBCO 
or United States Biochemical Corp. Uniformly labeled (U-^ C^)-glucose, 
(U-^ C^)-glucose-l-phosphate, l-(^ S^)-cystine, and Enhance autoradiography 
32 
enhancer were purchased from New England Nuclear. Carrier free P-
phosphorlc acid was a product of ICN. The radioimmunoassay kit for 
cAMP was obtained from Diagnostic Products Corp. Horse sera, fetal 
bovine sera, and penicillin-streptomycin mixture were purchased from 
M.A. Bioproducts. Viokase was a product of Viobin Corp. Spectramesh 
polypropylene filters (210 , sterile tissue culture plates (100 mm), 
and sterile capped test tubes (16 x 125 mm) were purchased from Fisher. 
Sterile 35 mm and 60 mm tissue culture plates were products of Lux 
Scientific Corp. Microporous filters (0.2 M-m) were from Amicon. Timed 
pregnant Sprague Dawley rats were ordered from Hilltop Labs. Rabbit 
skeletal muscle glycogen phosphorylase B and goat antisera to rabbit 
skeletal muscle glycogen phosphorylase A were generous gifts from Dr. 
D. J. Graves. Porcine skeletal muscle myosin and tropomyosin were gifts 
from Br. R. M. Robson. Chemically-fixed, protein A-bearing Staphylococcus 
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aureus bacteria were a gift from Dr. G. S. Cox. PGE^  was a gift from 
Dr. D. Dyer and the aminopropylsilane silica column was a gift of 
Dr. D. J, Reed. 
Methods 
Biochemical preparations 
Preparation of radiobiochemicals UDP-(U-^ C^)-glucose was made 
35 by the method of Thomas et al. (115). 1-( S)-cysteine was prepared 
35 from 1-( S)-cystine by reduction with DTT and cysteine immediately 
before use. 
Preparation of heart cell media CMRL 1415-ATM basal medium was 
prepared according to Healy and Parker (116). Basal medium was stable 
up to two months when stored in the dark at 4°C. 
Heart cell growth medium was composed of 90% CMRL 1415-ATM basal 
medium, 5% fetal bovine serum, and 5% horse serum. Serum lots were tested 
before use by observing their effect(s) on the beating rate, growth 
rate, and appearance of the heart cells. Serum was stored at -20°C 
up to sixteen months with no change in ability to support cell growth 
or beating. Growth medium was generally used within two weeks of sera 
addition. 
Preparation of Viokase solution A 0.1% solution of Viokase 
was prepared immediately before use. Viokase was solubilized in PBS, 
pH 7.4 by gentle mixing for 60 minutes at 37®C. Particulate matter 
was removed by filtering with Whatman No. 4 filter paper, and the 
solution was sterilized by filtering with a microporous filter (0.2 pm). 
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Preparation of heart cell cultures 
Heart cell cultures were prepared according to Harary et al. (117). 
This method involves isolating hearts from neonatal rats and dissociating 
the tissue to its component cells. 
A typical preparation of cell cultures was made from the combined 
litters of 5 rats (~ 50 pups). Hearts were removed from 2-day neonates 
and transferred to a petri dish containing cold growth medium. After 
collection of all hearts, they were shredded with scissors and trans­
ferred to a spinner flask. Hearts were digested by adding approximately 
1 ml of Viokase solution per heart and incubating at 37°C for 18-
minute intervals. The tissue was kept suspended during incubation by 
stirring at a slow rate. After incubation, the supernatant was decanted 
from undigested heart tissue into sterile test tubes. The test tubes 
were cooled in an ice-water bath for 8 minutes and then the cells were 
pelleted by a low speed centrifugation. The resulting cell pellet was 
re suspended in 5 mis of growth medium and kept on ice. Generally 8-10 
digestions were collected and the cell suspensions combined. The sus­
pension was filtered through a sterile filter (210 pm) and a sample of 
the filtrate was removed to determine cell concentration with a Coulter 
Counter. Then the cell suspension was diluted with medium to a concentra­
tion of 2.3 X 10® cells/ml, transferred to 100 mm tissue culture 
plates (15 mis/plate), and incubated at 37°C for 60 minutes. Following 
incubation, the plates were gently swirled and the suspension pipetted 
off. This "pre-plate" step served to remove rapidly attaching fibro­
blasts from the myocyte population. The cell suspension was counted 
again, and then diluted to a concentration of 1.7 x 10^  cells/ml. 
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Typical cell yields were about 3.4 x 10^  cells per heart. The cell 
suspension was plated at ratios of 2 mls/35 mm plate and 5 mls/60 mm 
plate. Cultures were maintained at 37°C in a humidified atmosphere and 
media changes were made every 24 hours beginning 18 hours after plating. 
To estimate the percentage of cells which were myocytes, the number 
of cells which were beating 30 hours after plating was determined in a 
typical cell preparation. In 5 randomly selected plates in which a 
total of 369 cells were counted, 93 + 3% of the cells were beating. 
Pre-plate cultures in which 3 plates and a total of 194 cells were 
counted, had only 7 + 11% beating cells. Although these values 
may vary in different cell preparations, it seems clear that the 
majority of cells which were plated were myocytes. Cultures were 
generally used for experimentation the fourth day after plating, 2-6 
hours after a medium change. 
Cell beating An inverted microscope with a video monitor was 
used to observe heart cell beating. All beating studies were conducted 
at 37°C and beating rates were determined by counting the contractions 
over a given time period. 
Preparation of cell cultures for assay 
Cell harves tine and extract preparation Unless stated other­
wise, cultures were harvested by aspirating media, rinsing with ice 
cold PBS, and adding liquid nitrogen directly to the cultures. Cells 
were stored frozen at -70oC or at liquid nitrogen temperature. Crude 
homogenates were prepared directly from frozen cultures. Frozen cell 
sheets were thawed by addition of ice cold homogenization buffer. 
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scraped off the plate with a rubber policeman, and sonicated at 5°C 
with a Branson Cell Disruptor. 
Preparation for glycogen synthase and glycogen phosphorylase assay 
Extracts were made in 50 mM Tris-HCl, pH 7.8, 5 mM EDTA, 5 mM EGTA, 
100 mM KF at a ratio of 100 pl/35 mm plate. The extract was centrifuged 
at 10,000 X g for 10 minutes at S^ C. The supernatant was used directly 
for assay of glycogen synthase and was diluted with 3-4 volumes of 40 mM 
B-glycerol phosphate, pH 6.8, 5 mM DTT for assay of glycogen phosphory­
lase. The of glycogen synthase for glucose-6-phosphate was 
determined in the 10,000 x g supernatant fraction after passage over 
Sephacryl S-300 (118) or Sephadex G-25 (119). 
Preparation for cAMP assay Cell cultures used for cAMP measure­
ment were harvested by the addition of ice cold 10% TCA instead of 
liquid nitrogen. The TCA-extracted material, along with precipitated 
protein was transferred to a test tube for centrifugation. The re­
sulting supernatant was extracted 4 times with ether acidified with 
0.1 N HCl, lyophilized, and suspended in assay buffer. Recovery of 
3 
cAMP (determined with an Internal standard of ( H)-cAMP) was over 90%. 
Preparation for glycogen assay Glycogen was Isolated from 
frozen cultures by the method of Walaas and Walaas (120) in which glycogen 
was precipitated with 66% ethanol after solubillzlng tissue in 0.4 ml 
of hot 30% potassium hydroxide. The precipitated glycogen was solublllzed 
in water. 
18 
Immunoprecipitation of glycogen phosphorvlase 
32 Glycogen phosphorylase was immunoprecipitated from P-labeled 
heart cells with chemically-fixed, protein A bearing-Staphvlococci (121). 
Cells (60 mm plates) were sonicated at 5°C in 200 nl of 50 mM Tris-HCl, 
pH 7.5, 10 mM EDTA, 150 mM NaF, 0.1 mg/ml BSÂ. The cell homogenate 
was centrifuged at 10,000 x g for 10 minutes at 5°C, and Tween-20 was 
added to the resulting supernatant to a final concentration of 0.1%. 
To reduce nonspecific binding, a pre-precipitation step with normal 
goat sera was employed. Twenty til of normal goat sera and 50 p,l of 
Staphylococci (20% w/v) were added to the supernatant fraction. The 
supernatant was then incubated at room temperature for 20 minutes. 
Nonspecifically bound material was pelleted by centrifugation in a 
Beckman microfuge for 2 minutes. The resulti' supernatant was 
incubated for 60 minutes at room temperature after addition of 20 i^l 
cf immune sera. Staphylococci (50 p.1) were then added, and the incuba­
tion was continued at room ten^ erature for 20 minutes. Immune complexes 
were precipitated by centrifugation in a Beckman microfuge for 2 minutes. 
The pelleted complexes were washed twice with 100 p.1 of 50 mM Tris-HCl, 
pH 7.5, 10 mM EDTA, 150 mM NaF, 0.1% Tween-20. The complexes were 
solubilized, denatured, and dissociated by resuspending the pellets in 
a buffer containing 65 mM Tris-HCl, pH 6.8, 2% SDS, 20 mM DTT, 20% 
glycerol, 0.001% bromphenol blue, and heating for 5 minutes at 
950C. 
19 
Assays 
Glycogen synthase Glycogen synthase was assayed by incorporation 
of (^ C^)-glucose from UDP-(^ C^)-glucose into glycogen according to 
Thomas et al, (115). Total glycogen synthase activity was measured in 
the presence of 10 jnM glucose-6-phosphate and glycogen synthase I was 
measured in the presence of 14 mM NagSO^  (122). The ratio of the 
activity in the presence of 14 mM Na^ SO^  to that in the presence of 
10 mM glucose-6-phosphate multiplied by 100 is defined as percent 
glycogen synthase I. 
Glycogen phosphorylase Glycogen phosphorylase was assayed by 
incorporation of (^ C^)-glucose from (U^ C^)-glucose-l-phosphate into 
glycogen according to Gilboe et al. (123). Total glycogen phosphorylase 
activity was measured in the presence of 1 mM AMP and glycogen phos­
phorylase A was measured with no added AMP. The ratio of activity in 
the absence of AMP to that in the presence of 1 mM AMP multiplied by 
100 is defined as percent glycogen phosphorylase A. 
Biological thiols Glutathione and cysteine were analyzed by 
the HPLC method of Reed et al. (124). Before analysis, samples were 
deproteinated by addition of PCA to a final concentration of 3.5% and 
removal of precipitated protein by centrifugation. The supernatant 
was reacted with iodoacetic acid to convert free thiols to s-carboxymethyl 
derivatives, followed by derivatization of the free amino groups by 
reaction with dinitrofluorobenzene. The derivatized thiols were 
separated by adsorption onto an aminopropylsilane silica column and 
elution with a 5-95% sodium acetate (0.8 M) gradient in 80% methanol. 
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Standards were used to determine retention times and amount of thiol. 
Peak heights were proportional to amount of thiol. 
cAMP cAMP was assayed with a commercial kit based upon 
the competitive protein binding assay of Oilman (125). Samples con-
3 
taining cAMP were added to a reaction mixture containing ( H)-cAMP and 
3 
a cAMP binding protein. Displacement of ( H)-cAMP was proportional to 
the amount of unlabeled cAMP present in the reaction. 
Glycogen and protein Glycogen was assayed by the phenol sul­
furic acid method as described by Dubois et al. (126). Glucose served 
as the standard. 
Protein was determined by the method of Lowry et al. (127) using 
crystalline bovine serum albumin as the standard. 
Electrophoretic procedures 
SDS-polyacrylamide gel electrophoresis was performed according to 
Laemmli (128). Linear gradient gels were made with an ISCO 570 gradient 
former. TEMED and ammonium persulfate concentration were reduced to 
0.01% in the gradlcnî: gels. All gels wêrê allowed to sic overnight 
before use. After electrophoresis, gels were stained overnight In 50% 
methanol, 10% acetic acid, 0.25% Coomassie Brilliant Blue R-250. Gels 
were destalned in 10% acetic acid, 10% isopropanol, and then equilibrated 
in 10% acetic acid, 10% glycerol before drying with a vacuum gel dryer. 
35 Gels of S-labeled proteins were routinely treated with Enhance before 
drying. 
Autoradiograms of dried gels were made using Kodak SB-5 film. 
Film was developed by standard methods. 
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RESULTS 
Alpha- and Beta-Adrenergic Effects on Heart Cell Beating Rate 
The effect of phenylephrine and isoproterenol on the beating rate 
of heart cells is shown in Figure 1. Stimulation with the «-adrenergic 
agonist, phenylephrine, produced an increase in the beating rate which 
did not change for 14 minutes. The p-adrenergic agonist, isoproterenol, 
produced a transient peak of increased rate followed by a stable plateau 
rate that was increased over the basal rate. Thus, these two adrenergic 
hormones have different effects on the heart cell beating rate. To 
determine the receptor specificity of these responses, the effect of 
adrenergic antagonists on the response to phenylephrine and isoproterenol 
was examined (Table 1). The P-antagonist, propranolol, inhibited iso­
proterenol stimulation of beating by 90%, but had no effect on the 
phenylephrine response. Thus, isoproterenol stimulation of the beating 
rate is p-receptor-mediated but phenylephrine stimulation is not mediated 
by this receptor. The »-antagonist, phenoxybenzamine inhibited the 
response to phenylephrine by 75%, démonstratiiig the ocreceptor dependence 
of the phenylephrine response. These results show that heart cell 
beating can be stimulated by «- or P-adrenergic activation. Since 
P-adrenergic responses generally result from increased cAMP levels 
in the cell, the effect of isoproterenol on the beating rate may be 
cAMP-mediated. Since phenylephrine stimulation of beating was un­
changed by propranolol, the crresponse may occur without increases in 
cAMP. 
The cAMP concentration in unstimulated heart cells was 6-9 pmoles/ 
Figure 1. The effects of phenylephrine and Isoproterenol on the beating rate of rat heart cells. 
Beating rates were determined as described in the Methods. Agonists were added directly 
to the cultures as aqueous stocks. Adding the agonist, mixing, and replacing the, culture 
on the microscope took approximately 20 seconds. The time 0 point represents the heart 
cell beating rate before agonist addition. At the time indicated by an arrow, the fol­
lowing additions were made; A) 10"phenylephrine, B) 10~5M Isoproterenol 
BEATS/MINUTE 
O 
O 
o o 
T-
2 M 
z 
m 
lA 
BEATS/MINUTE 
£Z 
24 
Table 1. The effect of adrenergic antagonists on the beating responses 
to phenylephrine and isoproterenol in rat heart cells^  
Beating rate 
(beats/min) Stimulation 
Treatment Basal Final (% of basal) 
lo" phenylephrine 84 111 132 
10" propranolol, 10 phenylephrine 71 94 132 
lo" phenoxybenzamine, 10 phenylephrine 78 84 108 
10' isoproterenol 74 110 149 
10' propranolol, 10 isoproterenol 76 80 105 
B^asal beating rates were determined 1 minute before addition of 
an agonist. Final beating rates were determined 1 minute after ad­
dition of an agonist. Antagonists were added 5 minutes before agonist 
addition. Additions of agonists and antagonists, and determination 
of beating rates were performed as described in Figure 1. 
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mg protein. This value is in good agreement with the concentrations 
found in the intact heart (82, 129). Since protein content varied 
less than 5% among replicate cultures, cAMP concentrations are ex­
pressed on a per plate basis in the following studies. The effect of 
phenylephrine and isoproterenol on heart cell cAMP levels is shown in 
Table 2. Isoproterenol-induced cAMP increases were inhibited 90% by 
propranolol. Isoproterenol stimulation of heart cell beating is as­
sociated with increased cAMP, because both effects were equally pre­
vented by propranolol (Tables 1 and 2). Phenylephrine increased cAMP 
levels only in the absence of propranolol. Since phenylephrine stimula­
tion of beating was unchanged by propranolol (Table 1), its beating rate 
effect is neither dependent upon or modified by increases in cAMP. 
These findings are consistent with the known mechanisms of action of 
a- and p-adrenergic hormones in other tissues. 
The «-adrenergic nature of phenylephrine-stimulated beating was 
examined using and or^ -specific adrenergic antagonists. Since 10"^ M 
phenylephrine increased heart cell cAMP levels (Table 2), a lower 
concentration of the hormone was used to study of-specific responses. 
Phenylephrine (10 ^ M) stimulation of the beating rate was prevented by 
the ttj^ -antagonist, prazosin, but not by the «g-antagonist, yohimbine 
(Table 3). Thus, 10 phenylephrine stimulates the heart cell beating 
rate by an cradrenergic mechanism involving the o^ -receptor. 
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Table 2. The effect of propranolol on phenylephrine- and isoproterenol-
stimulated cAMP increases in rat heart cells® 
Treatment cAMP (pmoles/plate) 
Basal 5.1 + 0.4 
lO'^ M propranolol 5.5 + 0.2 
lO'^ M phenylephrine 10.0 + i.o" 
1 o
 
1—1 
propranolol, 10 phenylephrine 5.7 + 0.1 
10"^ M isoproterenol 18.5 + 1.1^  
10"^ M _5 propranolol, 10 M isoproterenol 7.2 + 0.1^  
Incubations were terminated 40 seconds after agonist addition 
as described in the Methods. Propranolol was added 5 minutes prior 
to agonist addition. The results are expressed as the mean and 
standard deviation of duplicate experiments. 
p^ < 0.005 compared to appropriate control. 
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Table 3. The effect of o»-antagonists on phenylephrine stimulation of 
heart cell beating® 
Beating rate 
(beats/min) Stimulation 
Treatment Basal Final (% of basal) 
lo' phenylephrine 85 102 120 
t O
 prazosin, 10 phenylephrine 77 77 100 
lO' yohimbine, 10 phenylephrine 82 97 118 
B^asal beating rates were determined 1 minute before agonist ad­
dition. Final beating rates were determined 1 minute after agonist 
addition. Antagonists were added 5 minutes prior to agonist addition. 
Additions of agonists and antagonists, and determination of beating 
rates were performed as described in Figure 1. 
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Alpha- and Beta-Adrenergic Effects on Heart Cell cAMP 
In subsequent studies, it was found that epinephrine stimulated 
heart cell beating by both cr and P-adrenergic mechanisms (130). In 
these studies, the -^adrenergic beating response of epinephrine was 
unchanged by ofadrenergic antagonists. These results suggested that 
«-adrenergic stimulation had no effect on the p-adrenergic beating 
response of the heart cells. Since the g-adrenergic response was 
thought to be mediated by cAMP, this suggested that the adrenergic 
cAMP response was unmodified by of-adrenergic stimulation. However, 
cradrenerglc stimulation with phenylephrine is reported to reduce the 
cAMP response to isoproterenol in the perfused heart (21, 131). Thus, 
we examined the effect of of-receptor stimulation on ^ -receptor-mediated 
CAMP responses in heart cells. 
Figure 2 shows the dose response curves for isoproterenol and 
epinephrine on heart cell cAMP levels. The half maximal response to 
epinephrine occurs at a 4-fold higher concentration than isoproterenol, 
consistent with the kno:a affinities of these two agonists for the 
cardiac p-adrenergic receptor (132). 
To test the possible role of o*-stimulation on the cAMP response to 
epinephrine, the effect of ofj^ - and a^ -specific antagonists was examined. 
Neither prazosin (10 ^ M) nor phentolamine (10 ^ M) modified the time 
course of cAMP production from a submaximal dose of epinephrine (10 ^ M) 
(Figure 3A). The dose-response curve of epinephrine was similarly 
unaffected by either 10 or 10 yohimbine (Figure 3B). Concentrations 
-6 
of antagonists greater than 10 M had anomolous effects on the beating 
Figure 2. The effect of epinephrine and isoproterenol concentration on cAMP levels in rat heart 
cells. Heart cell cultures were incubated with agonists for 40 seconds and incubations 
were terminated as described in the Methods. Each point represents the mean of duplicate 
experiments. Oepinephrine, • isoproterenol 
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Figure 3. The effect of Of-adrenergic antagonists on the time course 
and concentration dependence of the cAMP response to 
epinephrine in rat heart cells. Antagonists were added 5 
minutes before epinephrine addition. Each point represents 
the mean of duplicate experiments 
A) At the times indicated after 10 epinephrine addition, 
incubations were terminated as described in the Methods. 
O no additions, X 10"prazosin, A10"7m phentolamine 
B) Incubations were terminated 40 seconds after epinephrine 
addition as described in the Methods. O no additions, 
X 10"^ M prazosin, A 10"% yohimbine 
32 
O 5 10 15 
MINUTES 
r- B 
15 
III 
< 10 
a 
N 
12 
I 
3- 5 
& 
s 
< 
6 
9 
V/ L _L I _L I 
•8 -7 -6 10 10 10* 10" 10 
EPINEPHRINE CONCENTRATION (M) 
r5 10^  
33 
rate of the heart cells, and such concentrations appear unnecessary in 
view of recent radioligand binding studies of these antagonists (133, 
134). In addition, 10 prazosin was completely effective in preventing 
phenylephrine (10 ^ M) stimulation of the beating rate (Table 3). Thus, 
both and adrenergic antagonists have no effect on the cAMP 
response to epinephrine. 
A second method of testing whether of-receptors modify P-mediated 
cAMP production is to use mixtures of cr and P-adrenergic agonists. 
Figure 4A shows that phenylephrine (10 ^ M) did not alter the time course 
of cAMP production from isoproterenol. The dose-response curve of iso­
proterenol was also unchanged by simultaneous phenylephrine stimulation 
(Figure 4B). Although phenylephrine is a more potent activator of o^ -
than o^ f^Gceptors (4), at 10 concentration, it probably stimulates 
both receptors. Since clonidine, epinephrine, and norepinephrine stimulate 
a^ -receptors (5), the effect of these agonists on isoproterenol stimula­
tion was examined. Table 4 shows that these agonists also had no ef­
fect on t!st cAMP response to isoproterenol. Thus, both and a^ -
adrenergic agonists did not reduce the P-adrenergic cAHP response in 
the heart cells. 
Desensitization of the Beta-Adrenergic Response 
Stimulation of heart cell beating by repeated addition of 
phenylephrine or isoproterenol revealed another difference between a-
and P-adrenergic responses in heart cells. Figure 5A shows that consecu­
tive additions of phenylephrine produced consecutive increases in the 
Figure 4. The effect of phenylephrine on the time course and concentra­
tion dependence of the cAMP response to isoproterenol in 
rat heart cells. Each point represents the mean of dupli­
cate experiments. Values have been corrected for cAMF 
produced by phenylephrine alone 
A) At the times indicated after isoproterenol (10 ^ M) 
addition, incubations were terminated as described in the 
Methods. O no additions, #+ lO'^ M phenylephrine 
B) Incubations were terminated 40 seconds after isoproterenol 
addition as described in the Methods. Qno additions, 
• + 10"% phenylephrine 
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Table 4. The effect of a-agonists on isoproterenol-stimulated cAMP 
increases in rat heart cells® 
Treatment cAMP (pmoles/plate) 
Basal 4.7 ± 0.2 
10"*M isoproterenol 20.2 .+ 1.1 
lO'^ M isoproterenol 21.0 + 2.7 
10"^ M isoproterenol + 10' •5M clonidine 20.0 + 0.4 
lO'^ M isoproterenol + 10' •5M norepinephrine 20.9 ± 1.7 
lO'^ M isoproterenol + lo' •5M epinephrine 21.2 ± 1.2 
Clonidine, norepinephrine, or epinephrine were added to iso­
proterenol and the mixture added to the cells. Incubation was 
terminated 40 seconds after addition as described in the Methods. 
The results are expressed as the mean and standard deviation of dupli­
cate experiments. 
Figure 5. The effect of repeated stimulation with phenylephrine or isoproterenol on the beating rate 
of rat heart cells 
A) At the times indicated by arrows, additions were made to give the following 
phenylephrine concentrations: a) 10"b) 10~7m, C) 10"d) 10"^ M, e) 10"^ M 
B) At the times indicated by arrows, the following additions were made: a) 10"iso­
proterenol, b) 10~®M isoproterenol, c) 10"^ M isoproterenol, d) 10"5m phenylephrine 
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beating rate of the heart cells. Thus, beating rate effects were not 
desensitized by sequential doses of phenylephrine, and a graded response 
was obtained over a 100-fold range of concentrations. In contrast, 
isoproterenol treatment of heart cells increased the beating rate and 
desensitized the cells to doses 10- and 100-fold higher (Figure 5B). 
The beating response to phenylephrine was not desensitized by the 
previous isoproterenol doses, suggesting that desensitization was 
specific for P-stimulation of beating. This latter finding confirms 
that a- and P-adrenergic hormones stimulate heart cell beating by dif­
ferent mechanisms. The finding that heart cells were desensitized by 
isoproterenol suggested that desensitization was P-receptor-medlated. 
Since the beating response to P-adrenergic agonists was associated 
with Increased cAMP, we examined whether the cAMP response to P-agonists 
was desensitized by previous p-stimulation of the cells. Figure 6 
shows the time course of the cAMP response to sequentially added doses 
of epinephrine from 10 ® to 10 ^ M. The lowest dose of epinephrine re­
duced the cAMP response to 10"^ M epinephrine by about 40% when compared 
to Figure 2. After addition of 10 epinephrine, there were no ap­
preciable Increases in cAMP following addition of higher concentrations 
of the hormone. Thus, epinephrine reduced or eliminated the response 
to higher concentrations of the hormone. Desensitization of the p-
adrenergic effect on the beating rate apparently results from desensitiza­
tion of the P-mediated cAHP response. 
The dose dependent nature of 8-agonist-induced desensitization is 
shown in Figure 7. Epinephrine (10 ^ M) or isoproterenol (10 ^ M) were 
used to produce a maximal cAMP response, and the reduction of this 
Figure 6. Desensitization of the cAMP response in rat heart cells by epinephrine. Incubations were 
terminated at the indicated time points as described in the Methods. Each point represents 
the mean of duplicate experiments. At the times indicated by arrows, additions were made 
to give the following epinephrine concentrations: a) 10"®M, b) lO'^ M, c) 10"6m, 
d) 10-% 
cAMP (pMOLES/PLATE) 
1^ 7 
Figure 7. The concentration dependence of epinephrine- and isoproterenol-induced desensitization of 
the cAMP response in rat heart cells. The heart cells were preincubated for 5 minutes at 
various agonist concentrations before addition of 10~^ M of the same agonist. Incubations 
were terminated 40 seconds after 10"agonist addition as described in the Methods. Each 
point represents the mean of duplicate experiments. 10~^ M epinephrine- and isoproterenol-
treated cultures with no prior treatment contained 20.4 + 1.0 and 23.6 ±1.1 pmoles 
cAMP/plate, respectively. O epinephrine, • isoproterenol 
_1_// L 1— 
O 10"' lO'® 10"' 
AGONIST CONCENTRATION(M) 
IN PREINCUBATION 
LO 
• 
_L_ 
10 1-6 
44 
response by incubating cells with lower concentrations of these hormones 
was examined. Half maximal desensitization with epinephrine occurred at 
a 5-fold higher concentration than for isoproterenol. The ability of 
an agonist to desensitize the cAMP response appears related to its 
ability to produce a cAMP response, since isoproterenol is more ef­
fective than epinephrine (Figures 2 and 6). A logical extension of 
these results is that desensitization might occur by a direct feedback 
mechanism on adenylate cyclase or cAMF phosphodiesterease by cAMP, or 
by the cAMP-promoted formation of inhibitors or activators, respectively, 
of these two enzymes. Such desensitization would be expected to be 
heterologous, being produced by any agent which increased cellular cAMP 
levels. 
To test the role of cAMP in P-adrenergic desensitization, the ef­
fect of P6E^  on the cAMP response to epinephrine was determined. 
PGE^  treatment of heart cells increased cAMP levels rapidly and in a 
dose dependent manner (Figure 8). The p-adrenergic antagonist, 
propranolol, had no effect on the cAMP response to PGE^ , but completely 
prevented an equivalent response from isoproterenol (Table 5). Thus, 
PGE^  effects on cAMP are not P-receptor-mediated. Table 6 shows that 
PGE^  significantly increased heart cell cAMP without desensitizing the 
cAMP response to epinephrine. A comparison of Figures 2 and 7 to Table 6 
shows that the CAMP response to PGE^  would have completely desensitized 
the epinephrine response if cAMP was the cause of desensitization. 
Instead, PGE^  and epinephrine produced additive effects on heart cell 
cAMP levels. These results indicate that g-adrenergic desensitization 
Figure 8. Time course and concentration dependence of the cAMP response 
to PGE]^  in rat heart cells. Each point represents the mean 
of duplicate experiments 
A) At the times indicated after 10 PGEj^  addition, incuba­
tions were terminated as described in the Methods 
B) Incubations were terminated 40 seconds after addition of 
the indicated concentrations of PGE^  as described in the 
Methods 
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Table 5. The effect of propranolol on isoproterenol- and PGE]^ -
stimulated cAMP Increases in rat heart cells® 
Treatment cAMP (pmoles/plate) 
Basal 5.7 + 0.2 
10 propranolol 5.6 + 0.4 
10 isoproterenol 13.9 + l.l" 
-5 -7 10 M propranolol, 10 M isoproterenol 4.9 + 0.2 
6 X lO'^ M PGE^  14.3 + 0.2^  
lO'^ M propranolol, 6 x 10 PGE^  14.3 + l.l" 
I^ncubations were terminated 40 seconds after isoproterenol or 
PGEi addition as described In the Methods. Propranolol was added 5 
minutes prior to hormone addition. The results are expressed as the 
mean and standard deviation of triplicate experiments. 
p^ <0.01 compared to appropriate control. 
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Table 6. The effect of PGE]^  on epinephrine-stimulated cAMP increases 
in rat heart cells® 
Net increase 
Treatment cAMP (pmoles/plate) over basal 
Basal 6.0 + 0.9 — 
10"^ M PGE^  17.7 ± 1.3 11.7 + 1.6 
"4 10 M epinephrine 19.1 ± 1.8 13.1 + 2.0 
10 M PGE^ , 10 M epinephrine 29.9 + 2.6 23.9 ± 2.8 
I^ncubations were terminated 40 seconds after epinephrine addi­
tion. PGEi was added 5 minutes prior to epinephrine addition as 
described in the Methods. When added alone, PGE^  was present 5 
minutes 40 seconds. Results are expressed as the mean and standard 
deviation of duplicate experiments. 
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in the heart cells is not due to an increase in the concentration of 
cAMP. Desensitization may represent a p-receptor-specific event. 
Adrenergic Effects on Glycogen Metabolism 
Regulation of glycogen metabolism by catecholamines is a complex 
process involving hormone receptors, second messengers, kinases, and 
the glycogen metabolizing enzymes. The heart cell responses to 
adrenergic agonists have shown that these cells possess ty and P-
adrenergic receptors and a hormone responsive adenylate cyclase. Ad­
ditional experiments showed the cells store glycogen and contain cAMP-
dependent protein kinase, glycogen phosphorylase, and glycogen synthase. 
Hence, the heart cells have the necessary components for a catecholamine 
responsive metabolism of glycogen. Since stimulation of glycogenolysis 
proceeds by activation of glycogen phosphorylase and inactivatlon of 
glycogen synthase, the effect of catecholamines on these two enzymes 
was studied. 
rreiiminary studies showed that the method of harvesting the heart 
cells influenced the basal activity state of glycogen phosphorylase. 
When cells were scraped off the culture plates and pelleted by centrifuga-
tion, percent glycogen phosphorylase A was quite high. This high value 
of phosphorylase was prevented by rapidly freezing the cells with liquid 
nitrogen (Table 7). Glycogen synthase activity was only slightly dif­
ferent with the two methods. Since the rapid freezing method provided 
typical basal activities of glycogen synthase and glycogen phosphorylase 
(82, 94, 135), it was adopted in subsequent studies of these enzymes. 
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Table 7. The effect of harvesting method on percent glycogen phos-
phorylase A and percent glycogen synthase I in rat heart 
cells 
Method % phosphorylase A % synthase I 
Cells pelleted in PBS* 54 13 
Cells rapidly frozen^  24 16 
C^ells were scraped off the plate in ice cold PBS, centrifuged 
for 4 minutes at 2000 x g, and the resulting cell pellet frozen. 
C^ells were harvested by liquid nitrogen addition to the plate as 
described in the Methods. 
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Initial studies of adrenergic effects on heart cell glycogen 
synthase were hampered by large variations in the activity state of 
glycogen synthase among replicate cultures. These variations were 
found to be related to the basal beating rate of the cultures. Figure 9 
shows that in cultures with rates above 150 beats/min, glycogen synthase 
activity was related to beating rate. The slower beating cultures had 
more typical glycogen synthase activity ratios which were unreleated to 
the beating rate. Subsequent experiments were conducted with cultures that 
were screened for beating rates below 150 beats/min. The percent glycogen syn­
thase I is inversely related to the glycogen concentration in the 
heart (95, 136, 137). This is thought to result from inhibition of 
glycogen synthase phosphatase activity by glycogen. To examine whether 
a similar relationship exists in heart cells, cells were incubated in 
glucose-free media for 24 hours to mobilize glycogen stores. As shown 
in Table 8, glucose starvation reduced glycogen levels and activated 
glycogen synthase dramatically. Thus, high activities of glycogen 
synthase in fast beating heart cells may be due to low glycogen levels 
in these cells. This was not tested directly because fast beating 
cultures could not be produced at will, but is consistent with an in-
crea^ id energy demand in these cells. The beating rates of the heart 
cells were not significantly altered by glucose starvation which also 
indicates that fast beating rates may be a cause rather than an effect 
of low glycogen concentrations. 
Figure 10 shows the time course of epinephrine's effect on glycogen 
phosphorylase and glycogen synthase activity in the heart cells. Glycogen 
phosphorylase was rapidly activated and glycogen synthase rapidly in-
Figure 9. The relationship between the beating rate and percent glycogen synthase I of rat heart 
cells. Heart cell beating rates were determined and cultures were harvested and assayed 
for glycogen synthase as described in the Methods. Each point represents a single 
culture of cells 
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Table 8. The effect of medium glucose removal on heart cell glycogen 
content and percent glycogen synthase I® 
Media Glycogen (mg/g protein) % synthase I 
+ glucose 81.0 + 0.4 13.6 ± 1.3 
- glucose 21.9 + 1.9 74.3 + 6.2 
C^ultures were incubated for 3 days in standard media (2.8 mM 
glucose). Then, half of the cultures received a standard media change 
and half were changed with glucose-free media. Incubation was 
continued for 24 hours and cultures were harvested and assayed for 
glycogen and percent glycogen synthase I as described in the Methods. 
Figure 10. Time course of epinephrine action on heart cell glycogen phosphorylase and glycogen syn­
thase activity. At the times indicated after epinephrine (10"^ M) addition, cultures were 
harvested and assayed for glycogen phosphorylase and glycogen synthase activity as 
described in the Methods. Total enzyme activities were not affected during the incuba­
tion with epinephrine. Each point represents the mean of duplicate experiments. 
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activated. These activity changes are consistent with phosphorylation 
of each enzyme. Thus, epinephrine regulates glycogen metabolism in 
the heart cells. Since epinephrine stimulates both o*- and adrenergic 
receptors, it is not clear which receptor(s) mediate(s) this response. 
The effect of cr and p-adrenergic stimulation on heart cell cAMP 
levels and glycogen phosphorylase activity is shown in Table 9. 
Phenylephrine treatment of the heart cells produced small increases 
in cAMP and percent glycogen phosphorylase A. This concentration of 
phenylephrine (10 ^ M) produced Cf-adrenergic effects on the beating 
rate of the heart cells (Table 3). Epinephrine and isoproterenol both 
increased cAMP and the percent glycogen phosphorylase A dramatically. 
These results indicate that hormones which increase cAMP are good 
activators of glycogen phosphorylase. To examine whether phenylephrine 
and epinephrine activated glycogen phosphorylase by of-adrenergic 
mechanisms, the effect of adrenergic antagonists was examined. 
Propranolol completely prevented the effects of phenylephrine, epinephrine, 
and isoproterenol on cAMP and glycogen phosphorylase. These results 
indicate that these hormones activate glycogen phosphorylase by a p-
adrenergic mechanism in the heart cells. Propranolol did cause a 
slight decrease in basal glycogen phosphorylase activity as observed in 
similar studies with skeletal muscle (96). The of-adrenergic antagonist, 
prazosin, did not prevent glycogen phosphorylase activation by epinephrine 
or isoproterenol, but did prevent the small effect of phenylephrine. 
Prazosin had an unexpected effect of slightly decreasing the cAMP 
response to the hormones, and this may account for the slight reduction 
in glycogen phosphorylase activation that occurred. When the percent 
Table 9. The effect of cr and P-adrenerglc stimulation on heart cell cAMP levels and the percent 
glycogen phosphorylase A® 
Treatment cAMP (pmoles/plate) % phosphorylase A 
Basal 5.7 ± 0.2 27.3 + 1.3 
10 ^ M phenylephrine 6.9 ± O.lh 32.8 ± 1.8» 
10 ^ M epinephrine 15.3 + 0.1^  69.1 ± 2.6» 
10 ^ M isoproterenol 13.9 ± 1.1» 60.6 + 1.0» 
10 ^ M propranolol 5.6 + 0.4 18.7 ± 0.4 
10 propranolol, 10 ^ M phenylephrine 5.1 ± 0.7 19.4 ± 0.1 
-5 -6 10 M propranolol, 10 M epinephrine 5.0 + 0.6 20.7 ± 1.8 
10"^ M propranolol, 10 isoproterenol 4.9 + 0.2 20.8 + 1.2 
10 M prazosin 5.6 + 0.1 26.3 + 0.8 
10 ^ M prazosin, 10 ^ M phenylephrine 6.0 + 0.2 27.4 + 0.7 
lO'^ M prazosin, 10 ^ M epinephrine 14.3 ± 0.1» 55.5 + 1.8» 
-6 -7 10 M prazosin, 10 M isoproterenol 13.5 + 0.2» 58.3 + 2.1» 
c^AMP was analyzed in duplicate cultures 40 seconds after hormone addition according to the 
Methods. The percent glycogen phosphorylase A was analyzed in triplicate cultures 1 minute 40 
seconds after hormone addition according to the Methods. Propranolol and prazosin were added 5 
minutes before hormone additions. The results are shown as the mean and standard deviation of the 
replicate experiments. 
p^ <0.01 compared to appropriate control. 
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glycogen phosphorylase A is compared to the cAMP concentration in 
these cultures (Figure 11), a very good correlation is observed 
(r = 0.98, p <0.001). These results indicate that catecholamines 
activate heart cell glycogen phosphorylase by a p-receptor-mediated, 
cAMP-dependent mechanism. 
Catecholamine effects on heart cell glycogen synthase activity are 
summarized in Table 10. Glycogen synthase was inactivated by isoproterenol 
or epinephrine, but not by phenylephrine. Changes in percent glycogen 
phosphorylase A may be a more sensitive indicator of increased cAMP 
than changes in percent glycogen synthase I, since phenylephrine activated 
phosphorylase without affecting synthase. Glycogen synthase inactiva-
tion by isoproterenol and epinephrine was completely prevented by 
propranolol and unaffected by prazosin. Propranolol affected basal 
synthase activity as seen with phosphorylase. These results indicate 
that glycogen synthase is inactivated by a P-adrenergic mechanism in 
heart cells. 
The effect of catecholamines on the activity of heart cell glycogen 
synthase was significant but quite small. In general, epinephrine ef­
fects on heart glycogen synthase have been difficult or impossible to 
observe by measurement of the glycogen synthase activity ratio. Recently, 
Mitchell and Thomas (75) showed that the for glucose-6-phosphate of 
purified cardiac glycogen synthase was a more sensitive indicator of the 
phosphorylation state than the activity ratio. The relationship between 
the A^ yg for glucose-6-phosphate and the percent I of heart cell 
glycogen synthase is shown in Figure 12. At low activities of glycogen 
synthase, the ^ H2 glucose-6-phosphate increases dramatically with 
Figure 11. The relationship between the cAMP level and the percent 
glycogen phosphorylase A of rat heart cells. The data 
of Table 9 were used to make this plot 
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Table 10. The effect of a- and |3-adrenergic stimulation on heart cell 
cAMP levels and the percent glycogen synthase 
Treatment cAMP (pmoles/plate) % synthase I 
Basal 5.7 + 0.2 13.6 + 0.6 
lO'^ M phenylephrine 6.9 ± 0.1^  14.7 ± 1.5 
10 epinephrine 15.3 + 0.1^  11.7 + 0.1^  
10 isoproterenol 13.9 ± 1.1^  10.6 + 0.9^  
lO'^ M propranolol 5.6 + 0.4 17.7 + 0.3 
-5 -6 10 M propranolol, 10 M phenylephrine 5.1 ± 0.7 17.4 + 1.1 
10 propranolol, 10 epinephrine 5.0 + 0.6 17.9 + 1.7 
-5 -7 10 M propranolol, 10 M isoproterenol 4.9 + 0.2 16.7 ± 0.4 
10 prazosin 5.6 + 0.1 14.1 + 0.6 
lO'^ M prazosin, 10 phenylephrine 6.0 + 0.2 13.2 + 1.1 
10 prazosin, 10 epinephrine 14.3 + 0.1^  10.5 + 0.6^  
"* 6 " 7 
10 M prazosin, 10 M isoproterenol 13.5 ± 0.2^  11.1 + O.l" 
c^AMP was analyzed as described in Table 9. Glycogen synthase per­
cent I vas analyzed in triplicate eultures 1 miuuUe 40 seconds after hor­
mone addition according to the Methods. Propranolol and prazosin were 
added 5 minutes before hormone addition. The results are shown as the 
mean and standard deviation of the replicate experiments. 
p^ <0.01 compared to appropriate control. 
Figure 12, The relationship between heart cell glycogen synthase activity measured as the percent I 
and as the ^ \j2 for glncose-6-phosphate. Cultures were harvested and prepared for assay 
as described in the Methods. Each point represents a determination made from an extract 
derived from 2 or 3 pooled cultures (35 mm plates). The Ax/2 for glucose-6-phosphate 
was estimated from Lineweaver-Burke plots of activity versus glucose-6-phosphate 
concentration. These plots were linear over a glucose-6-phosphate concentration 
range of 0.25 mM-10 mM 
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small decreases in the percent glycogen synthase I, Thus, we examined 
the effect of adrenergic hormones on the for glucose-6-phosphate 
of heart cell glycogen synthase. Figure 13 shows that isoproterenol 
treatment of heart cells increased the glycogen synthase for 
glucose-6-phosphate 2-fold, whereas phenylephrine treatment had no 
effect. 
Adrenergic Effects on Protein Phosphorylation 
P-adrenergic stimulation of heart cells produced activity changes 
in glycogen phosphorylase and glycogen synthase that are consistent 
with phosphorylation of these two proteins. To study the "in vivo" 
phosphorylation of these proteins, it is necessary to separate them 
from the large number of phosphoproteins present in the cell. Both 
glycogen phosphorylase and glycogen synthase are part of a protein-
glycogen complex in skeletal muscle and are recovered in a glycogen 
pellet fraction prepared from this tissue (138, 139). Table 11 shows 
thac heart cell glycogen phosphorylase and glycogen synthase are also 
recovered in a glycogen pellet fraction. Additional experiments with 
32 
P-labeled heart cells showed that the glycogen pellet fraction con­
tained about 30% of the protein and 25% of the TCA-insoluble radio­
activity of the crude extract. 
Adrenergic effects on protein phosphorylation were studied in a 
32 
soluble and glycogen pellet fraction prepared from P-labeled heart 
cells (Figure 14). Alpha-anylase digestion of the glycogen pellet 
was used to identify proteins which were bound to glycogen in this 
Figure 13. The effect of glucose-C)-phosphate concentration on glycogen synthase activity from 
control and catecholamine-treated heart cells. Incubation with hormones was for 
1 minute 40 seconds. Cultures were harvested and extracts prepared for assay according 
to the Methods. Each extract was derived from 2 plates (35 mm). O control, • 10" 
propranolol, 10"phenylephrine, ^  10"^ M isoproterenol 
1^/2 glucose-6-phosphate 
O 0,8 mM 
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Table 11. Recovery of heart cell glycogen phosphorylase and glycogen 
synthase activities in the glycogen pellet fraction® 
Number of 
centrifugations Fraction 
% crude extract 
Phosphorylase 
activity 
Synthase 
1 Pellet 90 98 
Supernatant 4 8 
2 Pellet 85 89 
Supernatant 4 8 
A^n extract was prepared by sonicating heart cells in 50 mM 
Tris-HCl, pH 7.8, 5 mM EDTA, 100 mM KF as described in the Methods. 
The resulting crude homogenate was split into 160 nl aliquots and 
centrifuged at 122,000 x g for 30 minutes at 5°C in a Beckman airfuge. 
The supernatants were removed and the pellets resuspended in buffer. 
To examine the effect of washing the first pellet, one of the resus­
pended pellets was subjected to a second centrifugation. Supernatant 
and pellet fractions were assayed for glycogen phosphorylase and 
glycogen synthase as described in the Methods. 
Figure 14. Scheme for preparation of soluble and glycogen pellet frac­
tions from rat heart cells. A crude homogenate was pre­
pared by sonicating a single culture (35 mm plate) in 
100 111 of 50 mM Tris-HCl, pH 7.5, 5 mM EDTA, 100 mM NaF. 
This was centrifuged at 10,000 x g for 10 minutes at 5°C 
to prepare the crude supernatant. Ultracentrifugations 
were performed at room temperature in a Beckman airfuge. 
Human salivary alpha-amylase was added to a final concentra­
tion of 10 M-g/ml 
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fraction. Since glycogen bound proteins would be rendered soluble by 
glycogen digestion, these proteins should be specifically removed 
from fraction E into fraction D. Proteins present in these fractions 
were separated by SDS-polyacrylamide gel electrophoresis on gradient 
gels in which mobility was proportional to the log of the protein sub-
unit molecular weight (Figure 15). An autoradiogram was developed from 
the gel, and the gel and autoradiogram are shown in Figure 16. The 
protein stain shows that fractions C and D contain a band which comigrates 
with glycogen phosphorylase (97,000 daltons). The location of this band 
in only these two fractions demonstrates it is a glycogen bound protein. 
32 The autoradiogram shows this band is P-labeled and was phosphorylated 
in response to isoproterenol but not phenylephrine (C-3, D-3). On the 
basis of this evidence, it is very likely that this protein is glycogen 
phosphorylase. Although activity measurements demonstrated that glycogen 
synthase was effectively precipitated by glycogen pelleting (Table 11), 
an 86,000 dalton band was not detected by protein stain or autoradiography 
in fractions C and D. The quantity of glycogen synthase in the heart 
cells is about 10% that of glycogen phosphorylase, so this result was 
not totally unexpected. More cells may be required to visualize glycogen 
32 
synthase than were used in this study. A P-labeled band with a molecular 
weight of 78,000 is glycogen associated, but is not visible by protein 
staining. This band appears to become dephosphorylated in response 
to p-adrenergic stimulation (C-3, D-3). 
32 P-adrenergic stimulation increased the P content of several 
other proteins which were not glycogen associated. A band with an ap­
parent molecular weight of 25,000 is visible in the autoradiogram 
Figure 15. The relationship between protein subunit molecular weight 
and electrophoretic mobility on SDS gradient-polyacrylamide 
gels. Linear gradient gels (5-15%) were prepared and SDS 
electrophoresis carried out as described in the methods. 
Standard proteins (1-2 |ig each) were run as internal stan­
dards for the gel shown in Figure 16. The mobility of 
these proteins with respect to the mobility of bromphenol 
blue is shown. Symbols for standard proteins and their 
molecular weights are: MY, porcine skeletal muscle myosin, 
200,000; PHK a, a subunit of rabbit skeletal muscle phos-
phorylase kinase, 140,000; PHK P subunit of rabbit 
skeletal muscle phosphorylase kinase, 120,000; PH, rabbit 
skeletal muscle glycogen phosphorylase B, 97,400; GS, bovine 
cardiac muscle glycogen synthase I, 86,500; BSA, bovine serum 
albumin, 68,000; TM 8, 0 subunit of porcine skeletal muscle 
tropomyosin, 36,000; TM a, a subunit of porcine skeletal 
muscle tropomyosin. 33.000: LY. egg white lysoe-ymej 15,000 
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Figure 16. The effect of o- and S-adrenergic stimulation on the incorporation of into proteins 
of rat heart cells. Heart cells were incubated with (0.85 mCi/ml) in phosphate-
free media for 1 hour Ijefore hormone additions. Cultures were harvested 1 minute 40 
seconds after hormone addition and fractions A-E prepared as described in Figure 14. 
SDS-electrophoresis on 5-15% linear gradient polyacrylamide gels was performed as 
described in the Methods. Eighty pg of fractions A, C, and E were applied to the gel. 
The amount of fractions B and D applied was proportional to the volumes of C and E used, 
respectively. The positions of the molecular weight standards (see Figure 15) are 
indicated. A, B, C, D, and E refer to the identity of the fraction (Figure 14). Lane 1, 
control; Lane 2, 10~5m propranolol, 10"phenylephrine; Lane 3, 10"^ M isoproterenol 
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in fractions B, C, D, and E. This band is apparent only after 3-
adrenergic stimulation. The location of the band in fractions B-E and 
absence in fraction A suggests this protein is loosely associated with 
the insoluble fraction of the heart cells. Six proteins associated 
with the soluble fraction were phosphorylated in response to p-
adrenergic stimulation (A-3). These proteins have apparent molecular 
weights of 236,000, 229,000, 161,000, 125,000, 102,000, and 86,000. 
Since the 236,000 and 229,000 dalton bands were beyond the range of the 
molecular weight standards, these estimates are less reliable. 
Immunoprecipitation of Heart Cell Glycogen Fhosphorylase 
The availability of a specific antibody to skeletal muscle glycogen 
phosphorylase A provided another possible method to isolate heart cell 
glycogen phosphorylase. Thus, we examined whether the antibody recog­
nized glycogen phosphorylase B or cross reacted with heart cell glycogen 
phosphorylase. Figure 17 shows the effect of phosphorylase antisera 
coiiCêûlrâûioii où precipitation of skeletal muscle glycogen phosphorylase 
B activity. Normal goat sera had no effect, but immune sera precipitated 
phosphorylase B in a dose dependent manner. Glycogen phosphorylase was 
present in this reaction in quantities which exceeded that to be isolated 
from the heart cells. Next, the immune precipitation of skeletal muscle 
glycogen phosphorylase B and heart cell glycogen phosphorylase were 
compared. Table 12 shows that phosphorylase antisera nearly quantitatively 
precipitated both skeletal muscle phosphorylase and heart cell phos­
phorylase. Thus, the antisera cross reacts with heart cell glycogen 
Figure 17. Inununotitration of skeletal muscle glycogen phosphorylase B with skeletal muscle glycogen 
phosphorylase A antisera. Skeletal muscle phosphorylase B (0.8 M<g) was Incubated in a 
40 M-l reaction containing 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mg/ml BSA and various 
dilutions of sera for 60 minutes at 30°C. Then, 100 iJ.1 of a 10% suspension of chemically-
fixed Staphylococcus aureus was added to adsorb the antigen-antibody complexes. After 
incubation for an additional 30 minutes at 30OC, the complexes were pelleted by a 2 minute 
centrifugation in a Beckman microfuge. The supernatant was assayed for glycogen phos­
phorylase as described in the Methods. • normal sera, O immune sera 
PHOSPHORYLASE ACTIVITY (CPM X 10"^ ) 
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Table 12. Immunoprecipitation of heart cell glycogen phosphorylase 
with antisera to skeletal muscle glycogen phosphorylase® 
Source of 7o of phosphorylase 
phosphorylase % phosphorylase A activity precipitated^  
Pure skeletal muscle 
phosphorylase B 1.5 98 
Heart cell extract 30.1 88 
Skeletal muscle phosphorylase and the heart cell extract were 
each incubated in a 50 nl reaction containing 50 mM Tris-HCl, pH 7.5, 
150 mM BaF, 10 mM ED TA, 0.1 mg/ml BSA, and 10 nl of normal or immune 
sera for 60 minutes at 22°C. Next, 25 pi of a 20% suspension (w/v) of 
chemically-fixed Staphylococci were added and the incubation continued 
for 20 minutes at 22®C. Immune complexes were pelleted by centrifuga-
tion and the supernatant assayed for glycogen phosphorylase according 
to the Methods. 
Activity is compared to the normal sera control. 
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phosphorylase, Reactivity does not appear to require phosphorylation of 
heart cell glycogen phosphorylase because 88% of the total activity was 
precipitated although only 30.1% assayed as the phospho-form. A control 
experiment showed that the activity state of heart cell glycogen phos­
phorylase was unchanged (31.3%) by the inmrunoprecipitation procedure. 
32 P-labeled heart cells were treated with o and P-adrenergic 
agonists, and glycogen phosphorylase was Isolated by immunoprecipitation. 
Immune complexes were separated by SDS-polyacrylamide gel electrophoresis 
and an autoradiogram was made from the dried gel. Immunoprecipitation 
of purified skeletal muscle glycogen phosphorylase B was used as a 
control. The results are shown in Figure 18. Comparing the skeletal 
muscle phosphorylase band in lane 1 to that precipitated by immune sera 
(lane 3) indicates that precipitation was quantitative based upon protein 
staining. These results are in agreement with the activity measurements 
of phosphorylase immunoprecipitation (Table 12), and suggest that there 
is good recovery of phosphorylase from the immunoprecipitated complex. 
Normal sera did not precipitate the skeletal muscle phosphorylase (lane 
2). Comparing lane 7 to lanes 4-6 shows that phosphorylase was the 
only visible heart cell protein specifically precipitated by the im­
mune sera. Lanes 4-6 appear to have equal amounts of phosphorylase 
based upon protein staining. Three proteins of apparent molecular 
weights of 200,000, 43,000, and 33,000 are found in lanes 4-7 but not 
in lanes 2 and 3. Thus, these proteins are heart cell-derived and 
were nonspecifically precipitated by the immunoprecipitation method. 
The autoradiogram shows that P-adrenergic stimulation of the heart 
32 
cells resulted in an increased P content of immune precipitated 
Figure 18. SDS electrophoresis of immunoprecipitates of glycogen phosphorylase. Immunopreclpitates 
were prepared from 32P"labeled heart cells and skeletal muscle glycogen phosphorylase B 
according to the Methods. Heart cell labeling with 32p and hormonal treatment was per­
formed as described in Figure 16. SDS-solubilized immune precipitates were subjected to 
electrophoresis on an polyacrylamide gel and an autoradiogram prepared as described in 
the Methods. The gel j.s shown on the left and the autoradiogram is on the right. Lane 1, 
molecular weight standards including 3.2 (ig of skeletal muscle glycogen phosphorylase B 
(Indicated by arrow); Lane 2, normal sera + skeletal muscle glycogen phosphorylase B 
(3.2 Mg) ; Lane 3, immune sera + skeletal muscle glycogen phosphorylase B (3.2 iJ-g) ; Lane 4, 
immune sera + control heart cells; Lane 5, immune sera + heart cells treated with 10"5m 
propranolol, 10"^M phenylephrine; Lane 6, immune sera + heart cells treated with 10~®M 
isoproterenol; Lane 7, normal sera + heart cells treated with 10"6M isoproterenol; Lane 
8, heart cell extract from control cells before immunoprecipitation 
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phosphorylase (lane 6). There appear to be three other major phospho-
proteins present in lanes 4-6 with apparent molecular weights of 90,000, 
43,000, and 33,000, The 90,000 and 33,000 dalton bands are present in 
lane 7 also, indicating that these proteins were nonspecifically precipi­
tated. The 43,000 dalton band is absent in lane 7, suggesting this 
protein was specifically precipitated by the phosphorylase antisera. 
Thiolation of Heart Cell Proteins 
Although a number of reports describe the effects of thiolation 
on activities of various enzymes "in vitro" (103-105), this form of 
covalent modification has not been described "in vivo" for any of 
these proteins. Heart cells were used to study protein thiolation 
"in vivo." Previous studies with liver cells indicate that both cysteine 
and methionine are incorporated into the glutathione pool in these 
cells (140). Since it is not clear whether heart cells have the 
35 
capacity to convert methionine into cysteine, we used S-cysteine to 
dctcCt the fcnnation of mixed—disulfides of glutathxcne and protein m 
the heart cells. Since cysteine can also be incorporated into the pep­
tide backbone of proteins, cycloheximide was used to inhibit protein 
synthesis. Thus, any label incorporated into protein via thiolation 
should be lost upon treatment of the proteins with reducing agent. 
35 
Figure 19 shows that heart cells incorporated S-cysteine into 
glutathione. Incorporation was linear with respect to time, aiid a cold 
chase with 1 mM cysteine prevented further labeling for the following 
30 minutes. At 60 minutes, the specific activity of glutathione was only 
Figure 19. The specific activity of the heart cell glutathione pool 
during (35s)-cysteine labeling. Heart cells (35 mm plates) 
were incubated in 0.5 ml of sulfur-free media supplemented 
with cycloheximide (5 VJ.g/ml) for 30 minutes at 37°C. Then, 
(^ S^)-cysteine (5 mM, 7.7 x 10^  cpm/pmole) was added and 
the incubation continued for periods of time up to 90 
minutes. At the times indicated, cultures were harvested 
as described in the Methods. Cell extracts were made by 
sonicating each culture in 50 m-I of 10 mM sodium phosphate, 
pH 7.0. Protein was precipitated from 25 m-I of each ex­
tract by addition of PCA to a final concentration of 3.5%, 
and the PCA-soluble material was analyzed for glutathione as 
described in the Methods. Radioactivity in glutathione was 
determined by collecting samples from the glutathione peak 
and counting by liquid scintillation. O untreated, # cold 
cysteine (1 mM) added at 60 minutes 
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0.04% of the medium cysteine specific activity, indicating that cysteine 
transport and/or glutathione formation is relatively slow. Reliable 
determinations of the specific activity of cellular cysteine were not 
possible due to contaminating medium cysteine. In spite of this prob­
lem, the data showed that the cysteine pool was not labeled appreciably 
faster than the glutathione pool. The levels of cysteine and glutathione 
remained constant during incubation and were 12 nmol/mg protein and 
19 nmol/mg protein, respectively. The level of oxidized glutathione was 
approximately 0,5-1.0 nmol/mg protein during incubation. 
35 
Heart cells Incubated with S-cysteine incorporated radioactivity 
into protein in a DTT-sensitive manner. A comparison of the uptake of 
label into glutathione and protein is shown in Figure 20. After a short 
lag period, label was Incorporated into protein at a rate similar to 
glutathione labeling. If the radioactivity incorporated into protein 
represents a mixed-disulfide with glutathione, it seems clear that 
protein thiolation is relatively rapid. To examine the chemical form 
of the radioactivity incorporated into heart cell protein, the experi-
35 
ment described in Figure 21 was performed. S-labeled heart cell 
protein was dialyzed to remove low molecular weight thiols and then 
treated with and without reducing agent. The proteins were precipitated 
and the supernatants were analyzed for thiols using HPLC. The DTT-
sensitive radioactive material was eluted from the column exclusively 
35 35 
as S-cysteine and S-glutathione. This result indicates that these 
two compounds were bound to heart cell protein by reduction sensitive 
bonds. 
The number and sizes of thiolated heart cell proteins were studied 
oc 
Figure 20. Comparison of ( S)-cy4iteine labeling of glutathione and protein in heart cells. The 
incubation of heart cells with (35s)-cysteine, the preparation of cell extracts, and 
the analysis of heart cell glutathione was performed as described in Figure 19. Radio­
activity incorporated j.nto heart cell protein was determined by measurement of TCA-
insoluble radioactivity. Heart cell extracts were incubated either with or without 
20 mM DTT for 20 minutes at 22°C, then aliquots were spotted on duplicate pieces of 
filter paper. The filter papers were washed extensively in 10% TCA, washed with 
acetone, dried, and counted. A) Radioactivity incorporated into glutathione. B) Radio­
activity incorporated into protein which was released by DTT treatment. This accounted 
for 55-80% of the total. TCA-insoluble radioactivity 
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Figure 21. HPLC analysis of radioactive material released by DTT-
treatment of (^ S^)-labeled heart cell protein. Heart 
cells were incubated with (^ 5s)-cysteine and harvested as 
described in Figure 19. A crude homogenate was prepared 
by sonicating 2 plates (35 mm) in 30 p.1 of 25 mM He pes, 
pH 7.0. The crude homogenate was centrifuged at 122,000 x g 
for 30 minutes in a Beckman airfuge at 22°C, and the re­
sulting supernatant was dialyzed against 10 mM sodium phos­
phate, pH 7.0 for 24 hours at 50C. The dialysate was split 
into 2 equal volumes and treated with and without 1 mM DIT 
for 20 minutes at 22oC. The protein was then precipitated 
by addition of PCA to a final concentration of 3.5%, and the 
FCA-soluble material was analyzed for thiols as described 
in the Methods. All fractions were collected and counted 
for radioactivity present. The positions of elution of 
cysteine and glutathione were determined with standards and 
are indicated in the figure as CYS and GSH, respectively, 
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Figure 22. SDS electrophoresis of (35s)-labeled heart cell proteins. 
A single culture (35 mm plate) of heart cells was incubated 
in 0.5 ml of sulfur-free media supplemented with cyclohexi-
mide (5 Mg/ml) for 30 minutes at 37°C. (35s)-cysteine 
(100 M.M, 2.2 X 10^  cpm/Mmole) was added and the incubation 
was continued for 64 minutes. The culture was harvested ac­
cording to the Methods, and a crude homogenate prepared by 
sonicatlon in 30 nl of 10 mM sodium phosphate, pH 7.0, 5 mM 
EGTà, 1 mM PMSF. The crude homogenate was centrifuged at 
122,000 X g for 30 minutes in a Beckman airfuge at 22°C. 
The resulting supernatant was split into 2 equal volumes and 
suspended in sample buffer either with or without 20 mM DTT. 
Protein samples were heated at 95®C for 5 minutes and the 
electrophoresed on an 8% polyacrylamide gel according to the 
Methods. An autoradlogram was prepared from the dried gel 
according to the Methods. The gel is shown on the right and 
the autoradlogram on the left. + and - refer to treatment 
with and without DTT, respectively. Positions of migration 
of molecular weight standards (see Figure 15) are indicated 
140 K-^ 
120K-to^ 
68 
36K-»-
33 
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with SDS-polyacrylamide gel electrophoresis. A soluble fraction of the 
heart cells was treated with and without DTT and the proteins separated 
by electrophoresis. Figure 22 shows the gel and resulting fluorogram 
from this experiment. The results show there is a large number of 
proteins thiolated in the heart cells, rather than a few specific proteins. 
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The amount of S associated with a given protein seems related to the 
protein's abundance; however, bands at 64,000 and 87,000 daltons appear 
to have more radioactivity than the protein stain would indicate. 
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DISCUSSION 
Beating heart cell cultures offer a means of studying molecular 
events underlying the action of cardioactive hormones at the cellular 
level. This report is the first in which an extensive study of 
catecholamine action on the heart cell has been examined. Some of this 
work can be compared to previous studies with heart cells, but other 
results will be compared to observations made in the perfused or in­
tact heart. 
Both a- and p-adrenergic stimulation increased the beating rate of 
the heart cells. These results are in agreement with previous studies 
on beating heart cells (40, 141). Beat-to-beat regulation in the heart 
is thought to be controlled by the entry of extracellular calcium which 
triggers calcium release from the sarcoplasmic reticulum (142). If 
heart cell contraction is regulated by a similar mechanism, then o-
and -^adrenergic stimulation of beating may be due to stimulation of 
"trigger calcium" entry, g-adrenergic stimulation of the heart cells 
was asRoeiflted with cAMP increases in this study. The transitory beating 
rate change produced by isoproterenol (Figure 1) corresponds to the time 
course of its effect on cellular cAMP levels (Figure 4). The P-
adrenergic antagonist, propranolol, had equivalent effects on inhibi­
tion of beating rate and cAMP changes resulting from isoproterenol 
treatment. In addition, both the cAMP response and the beating rate 
change were desensitized by previous p-adrenergic stimulation of the 
heart cells. Since derivatives of cAMP have been shown to increase 
the beating rate of heart cells (143-145), it seems likely that P-
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adrenergic effects on the beating rate are cAMP-mediated, Cyclic AMP-
dependent phosphorylation of sarcolemmal protein(s) involved in "trigger 
calcium" entry would provide a possible mechanism for p-adrenergic 
effects on the beating rate. Walsh et al. (146) observed that 
epinephrine treatment of perfused rat hearts caused phosphorylation of 
a 27,000 dalton protein present on sarcolemmal vesicles prepared from 
these hearts. Recently, Rinaldi et al. (45) demonstrated that cAMP-
dependent phosphorylation of a 23,000 dalton sarcolemmal vesicle protein 
stimulated the slow calcium channel of these vesicles. Thus, the 
phosphorylation of this protein may be involved in p-adrenergic effects 
on the beating rate of the heart cells. 
Phenylephrine stimulation of the heart cells produced beating rate 
changes which were stable and not dependent upon increases in cAHP. 
This response was not modified by previous a- or p-adrenergic stimula­
tion of the cells, and occurred when p-adrenergic effects on beating 
were completely desensitized. Thus, «-adrenergic effects on heart cell 
beating are mediated by mechanism(s) distinct from that of 3-adrenergic 
hormones. The adrenergic receptor eliciting the phenylephrine effect 
appears to be the Oj^ -subtype since the response was inhibited by prazosin 
and not yohimbine. In the perfused rat heart, phenylephrine stimula­
tion elevates the concentration of cGMP (21). It is unlikely that cGMP 
is involved in phenylephrine's effect on heart cell beating because 
derivatives of cGMP decrease the beating rate of heart cells (144). 
Many oradrenergic effects appear to involve increases in the concentra­
tion of cytosolic calcium (11). Of-Adrenergic stimulation increases 
cytostolic calcium by causing mobilization of intracellular calcium 
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stores and by promoting influx of extracellular calcium (11, 16). The 
mechanisms by which these two changes occur remains unknown, but it is 
possible that extracellular influx could be controlled by a connection 
of the a-receptor with the gating mechanism at the plasma membrane. 
The observed «-stimulation of the heart cell beating rate could be ex­
plained by such a mechanism as well as by a number of others. What is 
clear, however, is that the heart cells have a functioning of-receptor 
system and may be used to investigate cradrenergic regulation of 
metabolism. 
Heart cell cAMP metabolism was unaffected by (%-adrenergic activa­
tion in this study. Both basal and P-adrenergic-stimulated cAMP 
levels were unchanged by «-adrenergic stimulation. These findings are 
in contrast to those reported by Keely et al. (21) in which cf stimulation 
reduced p-adrenergic effects on cAMP, cAMP-dependent protein kinase, 
and glycogen phosphorylase in the perfused rat heart. These in­
vestigators did not determine the receptor specificity of the 
response, but found it could be elicited by either phenylephrine 
or epinephrine and prevented by high concentrations of phentolamine. 
Our study tested both and o^ s^pecific adrenergic effects on the 
time course and dose dependence of the cAMP response to p-adrenergic 
agonists. Since «-adrenergic inhibition of adenylate cyclase is thought 
to be mediated through receptors of the subtype (16), our findings 
could result from the absence of these receptors on heart cells. 
Radioligand binding studies have documented the presence of a-^ - and 
Q^ -adrenergic receptors in membranes prepared from the rat heart (6); 
however, similar studies have not been conducted with membranes from 
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beating heart cells- OJ-Adrenergic regulation of cAMP metabolism in 
the perfused heart (21) may also result from the variety of cell types 
present, the chronological.age of the cells, or a different mechanism 
of adrenergic action than found in heart cells. In adult heart myocytes, 
phenylephrine treatment was found to decrease the cAMP response to iso­
proterenol by a phentolamine-insensitive mechanism (131). Although 
these results are difficult to interpret, they are clearly different from 
the perfused heart study (21) and the work reported here. In any case, 
our studies indicate that cx- and P-adrenergic responses occur rather 
independently of one another in beating heart cells. The extent and 
duration of ^ -adrenergic responses are not controlled by o^ -receptor 
systems in these cells. 
This report is the first to describe desensitization of the p-
adrenergic response in heart cells. Desensitization was quite rapid 
(5 minutes) and represents a means of regulating -^adrenergic 
responsiveness in these cells. Since PGEj^  elevated cAMP levels without 
producing p-adrenergic desensitization, it seems clear that desensitiza­
tion is not cAMP-mediated as suggested in some studies (147, 148). 
However, in perfused heart, FGE^  increases cAMP and activates cAMP-
dependent protein kinase in cellular pools which are distinct from those 
which catecholamines affect (149-151). Thus, it is possible that PGEj^  
fails to Increase cAMP in the cellular pool responsible for p-adrenergic 
desensitization of the heart cells. This does not appear to be the 
case because PGEj^  activated glycogen phosphorylase and inactivated 
glycogen synthase to levels consistent with its observed effect on heart 
cell cAMP (data not shown). The rapidity of p-receptor desensitization 
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in the heart cells suggests it is due to a loss of receptor coupling 
to adenylate cyclase rather than a loss of adrenergic receptors from 
the cell membrane (25, 26, 152). Recent evidence suggests that this 
form of desensitization occurs by modification of the p-receptor itself, 
rather than modification of the regulatory component of adenylate cyclase 
(27, 153). In two separate studies, desensitization has been demon­
strated in the heart. Tse et al. (154) found that rat hearts became 
desensitized to "in vitro" isoproterenol stimulation by chronic injection 
of rats with isoproterenol. Desensitization appeared to result from a 
loss in receptor number instead of receptor-cyclase coupling. However, 
short incubation of chick embryo ventricles with isoproterenol was 
found to desensitize the heart membranes with no change in receptor 
number (155). Additional studies are needed to define the cause of 
P-receptor desensitization in the heart cells, but our studies demon­
strate that this response is more complex than simple responses to the 
cellular cAMP concentration. Desensitization of the heart cells is 
likely to involve primary events at the level of the p-receptor itself. 
This work represents the first demonstration of the hormonal 
control of glycogen phosphorylase and glycogen synthase in cultured 
heart cells. Epinephrine addition to heart cells produced a rapid 
activation of glycogen phosphorylase, in agreement with studies on 
the perfused heart (76, 82, 83, 88, 90, 149, 150, 156-162) and intact 
heart (86, 87, 92, 94). Activation always occurred following P-
adrenergic stimulation, but was not elicited by «-adrenergic stimula­
tion with phenylephrine or epinephrine. These results confirm previous 
studies on the perfused and Intact heart in which epinephrine stimulation 
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of glycogen phosphorylase was found to be B-adrenergic-mediated (82, 
87, 90, 92, 94, 156, 160). Recently, a-adrenergic activation of 
glycogen phosphorylase was described in hearts from diabetic rats 
(90) and hearts which were depleted of glycogen (91). The signifi­
cance of a-adrenergic activation of glycogen phosphorylase remains 
obscure, since it does not occur under normal physiological conditions. 
Since activation of glycogen phosphorylase occurs by phosphorylation 
of the protein, we examined the effect of adrenergic stimulation on 
phosphorylation of glycogen phosphorylase in the heart cells. These 
studies clearly showed that phosphorylation occurred in response to 
p-adrenergic and not of-adrenergic stimulation and confirmed the activity 
measurements of glycogen phosphorylase. The temporal relationship 
that exists between elevation of cAMP and activation of glycogen phos­
phorylase by P-adrenergic stimulation of the heart cells (Figures 4 and 
10) is consistent with a role of cAMP in the activation process. 
This is supported by the observed relationship between heart cell cAMP 
levels and percent glycogen phosphorylase A (Figure 11). These results 
are in keeping with activation of phosphorylase kinase by phosphoryla­
tion with cAMP-dependent protein kinase. This has recently been 
demonstrated "in vitro" with the cardiac isozyme of phosphorylase kinase 
(67, 163, 164). 
Epinephrine treatment of heart cells inactivated glycogen synthase 
by a mechanism dependent upon ^ -adrenergic stimulation. These results 
support the work of Nuttall et al. (94) in which epinephrine administra­
tion to rats decreased the percent glycogen synthase I in the heart by 
a -^adrenergic mechanism. Besides Nuttall et al. 's work (94) and this study, 
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other attempts to demonstrate epinephrine action on cardiac glycogen 
synthase have met with little success. In the perfused heart, epinephrine 
has no detectable effect on percent glycogen synthase I (76, 82, 95) 
unless the basal percent synthase I is abnormally high (90) or the 
glycogen content is abnormally low (91). Since glycogen inhibits de-
phosphorylation of cardiac glycogen synthase "in vitro" (79) and its 
concentration is closely correlated to percent glycogen synthase I in 
the heart (95, 136, 137), it seems especially important to study the 
hormonal control of this enzyme in cells having normal glycogen 
concentrations. Since the concentration of glycogen in the heart cells 
is similar to values reported for the intact heart (92, 94, 165), our 
results are not due to atypical glycogen levels in the cell. The basal 
glycogen synthase activity of heart cells used in this study is typical 
of values reported for the heart (76, 80, 82, 90, 94, 95, 137), and 
suggests that heart cell glycogen synthase normally exists as a phos-
phoenzyme. The ability to inactivate heart cell glycogen synthase by 
a -^adrenergic mechanism suggests that the enzyme has sites available 
for phosphorylation by the cAMP-dependent protein kinase. Recently, 
Mitchell and Thomas (75) described the phosphorylation of purified 
bovine cardiac glycogen synthase I. Phosphorylation at two sites, 
termed site 1 and 2, was catalyzed by cAMP-dependent protein kinase, 
and a third site, site 3, was phosphorylated by a cAMP-independent 
glycogen synthase kinase. By analogy with the bovine enzyme, our 
results indicate that epinephrine may stimulate phosphorylation of 
site 1 and/or site 2 of heart cell glycogen synthase. The change in 
the Ai/2 for glucose-6-phosphate of heart cell glycogen synthase following 
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epinephrine treatment is more compatible with site 2 phosphorylation 
than site 1 (75). Since heart cell glycogen synthase has a basal per­
cent I and for glucose-6-phosphate that is not accounted for by 
any single phosphoenzyme species described by Mitchell and Thomas (75), 
the enzyme may exist as hybrids of these forms or in forms phosphorylated 
32 by other kinases. Glycogen synthase isolated from P-perfused rat 
32 hearts was recently found to have P present on two CNBr peptides (76). 
Using purified rat heart synthase, these workers demonstrated that one 
peptide was phosphorylated by cAMP-dependent protein kinase and the 
second by a cAMP-independent protein kinase. These results suggest 
that glycogen synthase forms similar to GS^  described by Mitchell 
and Thomas (75), may exist in the rat heart. With the development of 
methods to purify heart cell glycogen synthase, the heart cells provide 
the unique opportunity to describe epinephrine effects on the phosphoryla­
tion state of heart glycogen synthase. In addition, such studies may 
help clarify the "in vivo" phosphorylation state of the enzyme. 
Adrenergic effects on endogenous protein phosphorylation in beating 
heart cells have not been previously described. This study confirmed 
our observation of P-adrenergic regulation of heart cell glycogen phos-
phorylase and identified a number of other phosphorylated bands whose 
phosphorylation state is regulated by -^adrenergic stimulation. Stimula­
tion of the a-adrenergic receptor with phenylephrine did not produce 
detectable effects on cytosolic protein phosphorylation as found in 
rat hepatocytes (166). This may result from major differences in 
catecholamine action in these two cell types, since hepatic glycogenolysis 
is activated by a-adrenergic agonists by mechanisms involving calcium 
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ions and not a rise in cAMP (12, 167-169). In the heart cells, this 
study has shown that adrenergic effects on glycogen phosphorylase and 
glycogen synthase occur solely by p-adrenergic mechanisms. Although 
it is likely that a number of heart cell proteins migrate at similar 
molecular weights (170), it is interesting to attempt identification 
of other phosphorylated bands which were regulated by P-adrenergic 
stimulation. The 25,000 dalton protein associated with the insoluble 
fraction may represent troponin I. The observed molecular weight is 
close to the published value of cardiac troponin I (52, 171), and troponin 
I is known to be phosphorylated during adrenergic stimulation of the 
heart (52, 158, 172), Our observation of p-adrenergic stimulation of 
the heart cell relaxation rate (173) is in keeping with troponin I 
phosphorylation. The location of the 25,000 dalton protein in the 
insoluble fraction may be due to association with actin. Actin repre­
sents a major protein of the glycogen complex in skeletal muscle (174), 
and a protein with.a molecular weight of 40,000 is a major protein of 
the glycogen pellet from heart cells (Figure 16). Since the glycogen 
pellet fraction probably contains sarcoplasmic reticulum proteins also, 
the 20,000-22,000 dalton protein, phospholamban, is another possible 
candidate for the 25,000 dalton heart cell protein. Phospholamban is 
a known substrate of cAMP-dependent protein kinase (48) and has recently 
been reported to become phosphorylated upon g-adrenerglc stimulation 
of the perfused heart (51, 172). Since phospholamban phosphorylation 
is thought to increase the uptake of calcium by sarcoplasmic reticulum 
(35), it could also account for P-adrenergic stimulation of heart cell 
relaxation rate. The 125,000 dalton protein present in the soluble 
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fraction of the heart cells has a molecular weight identical to that of 
the p-subunit of cardiac phosphorylase kinase (163), In the perfused 
heart, phosphorylase kinase is phosphorylated and activated by epinephrine 
treatment (175). Phosphorylation occurs on both the a'- and P-subunits, 
and enzyme activation correlates well with total phosphorylation. Ad­
ditional studies have shown that phosphorylation of either the o'-
or P-subunit by cAMP-dependent protein kinase activates the enzyme 
"in vitro" (67). Since glycogen phosphorylase is activated in the 
heart cells by P-adrenergic stimulation, it is likely the 125,000 dalton 
protein is the P-subunit of phosphorylase kinase. The location of this 
protein in the soluble fraction is in agreement with studies of glycogen 
association of the skeletal muscle enzyme (138, 176). The possible 
identities of the proteins with subunit molecular weights of 236,000, 
229,000, 161,000, 102,000, and 86,000 are not known. Recently, the 
effects of inotropic agents on protein phosphorylation were studied 
in adult rat myocardial cells (177). Although these cells are quite 
different from beating heart cells, they serve as the best available 
comparison to our study. These investigators found that p-adrenergic 
treatment stimulated phosphorylation of proteins of apparent subunit 
molecular weights of 150,000, 94,000, 33,000, 28,000, and 12,000. 
The 94,000 and 28,000 dalton proteins were suggested to be glycogen 
phosphorylase and troponin I, respectively, but identity of the other 
bands was not made. Thus, a comparison of the proteins phosphorylated 
in response to P-adrenergic stimulation in these two studies shows some 
similarities and differences. The similarities may represent es­
sential regulatory phosphorylations and differences may represent 
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phosphorylations associated with unique functions of each cell. 
The apparent dephosphorylation of a glycogen-associated 78,000 
dalton protein in response to P-adrenergic stimulation was an unex­
pected result in this study. However, isoproterenol was recently 
32 32 found to decrease the P content of a 30,000 dalton protein in P-
incubated heart muscle slices (178). Our result could be explained by 
a P-adrenergic-stimulated phosphorylation and inactivation of a protein 
kinase, as postulated to occur with the myosin light chain kinase in 
smooth muscle (179). Activation of a protein phosphatase by a mechanism 
involving cAMP-dependent phosphorylation could also account for our 
observation. In skeletal muscle, protein phosphatase inhibitor 1 be­
comes activated by phosphorylation in response to epinephrine (180). 
Although the net effect is opposite of that described here, it demonstrates 
the existence of ^ -adrenergic regulation of protein phosphatases. Since 
the 78,000 dalton protein was not visible by protein stain, it is also 
likely that P-adrenergic stimulation reduced the amount of this protein 
associated with the glycogen pellet. This could occur by a number of 
mechanisms including p-adrenergic-stimulated proteolysis of the protein 
or a decreased affinity of the protein for glycogen after its phos­
phorylation. Oxidation of liver glycogen synthase decreases the af­
finity of this protein for glycogen (181). 
35 Our study of S-cysteine labeling of heart cell proteins confirms 
the idea that protein thiolation occurs "in vivo." These studies 
demonstrate that a large number of soluble heart proteins form mixed-
disulfides with glutathione and cysteine in the cell. Thiolation ap­
pears to be a rapid process in the heart cells, since the rate of labeling 
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of protein was similar to glutathione and cysteine labeling. Thus, the 
extent of protein thiolation in the cell may be able to change rapidly 
in response to cellular stimuli. Recently, a cytoplasmic thioltrans-
ferase which catalyzes the formation and breakdown of mixed-disulfides 
of proteins and glutathione has been purified from rat liver (110, 182). 
It seems likely that protein thiolation in the cell is enzyme catalyzed 
because the reaction proceeds very slowly at neutral pH using purified 
proteins (103, 106). The large number of heart cell proteins modified 
by thiolation suggests that this form of protein modification may represent 
a generalized mechanism for modulating protein function in a manner 
similar to phosphorylation of proteins. Recent studies by Keeling et al. 
(113) suggest that the activity of the pentose phosphate pathway may 
be regulated by protein mixed-disulfide formation "in vivo." This idea 
is in keeping with the observed stimulation of glucose-6-phosphate de­
hydrogenase by oxidized glutathione (107). Thus, protein thiolation 
may provide a mechanism for stimulating glucose-6-phosphate dehydrogenase 
activity in the presence of inhibitory NADPH concentrations "in vivo." 
Fructose bisphosphatase is inhibited by the concentrations of AMP nor­
mally present in the cell, but an inverse relationship between cytosolic 
AMP concentration and the rate of hepatic gluconeogenesis is not found 
(183). Recently, Moser et al. (184) purified an oxidized and reduced 
form of fructose bisphosphatase from rat liver and found that the oxidized 
form was significantly less sensitive to AMP inhibition "in vitro." 
This enzyme has previously been shown to be activated by reaction with 
biological disulfides by Pontremoli and Horecker (106). The enzyme 
catalyzing the reverse reaction, phosphofructokinase, has recently been 
106 
shown to become reversibly inactivated by incubation with oxidized 
glutathione (105). These findings suggest the possibility of regula­
tion of hepatic gluconeogenesis by concerted thiolation of fructose 
bisphosphatase and phosphofructokinase. Thomas et al. (109) has recently 
shown that the inhibition of dephosphorylation of cardiac glycogen 
synthase by glycogen was changed by oxidation of glycogen synthase. 
Reaction of glycogen synthase with oxidized glutathione caused a 
shift in the glycogen inhibition curve to higher glycogen concentra­
tions, demonstrating that the oxidized enzyme is a better substrate 
for dephosphorylation than the reduced enzyme. Treatment of the per­
fused heart with insulin shifts the relationship between percent glycogen 
synthase I and glycogen content in a similar fashion (137). Although 
this insulin effect may be due to changes in glycogen synthase phospha­
tase (80, 81), it is interesting to speculate that thiolation of 
glycogen synthase may also be involved. In any case, it seems quite 
likely that thiolation of proteins "in vivo" represents a metabolically 
important modification. The method developed in this study to examine 
thiolation "in vivo" represents an Important step in studying the 
regulation of this process. 
The work reported here suggests that beating heart cells can be 
successfully used to study adrenergic regulation of beating, cAMP 
metabolism, receptor desensitizatlon, glycogen metabolism, and protein 
phosphorylation. It is likely that these cells can be used to study 
other aspects of heart metabolism such as protein thiolation and the 
action of other hormones such as insulin. Such investigations may 
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help to provide a more complete picture of metabolism and hormonal 
regulation of the myocardial cell. 
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